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SUMMARY                
Cancer is a major cause of morbidity and mortality worldwide. Cancer is the second most 
frequent cause of death and is becoming the leading cause of death in an ageing population, as 
most cancers occur in older adults; of note, cancer-related malnutrition is the immediate cause 
of death of 20% of the patients with cancer. Notwithstanding that different cancer types or 
locations may display different nutritional patterns, there is some inconsistency between studies 
in what concerns nutritional status assessment and cancer/treatment-related variables. A 
thorough analysis of their interaction is long due, in order to step forward the eagerly awaited 
evidence to foster the integration of appropriate nutritional therapy. Moreover, although 8 to 
84% of cancer patients may present some degree of nutritional deterioration, which has been 
associated with functional impairment, the interaction between nutritional status and intake, 
symptoms and other disease/treatment-related factors, is a complex combination which may 
dictate patients’ Quality of Life (QoL). Nevertheless, the multitude of interactions between 
cancer location and stage, treatments, nutritional status and intervention, morbidity and QoL 
has never been thoroughly explored. The evidence for these interactions will be demonstrated 
in this thesis, which results from the collision of data from several prospective studies conducted 
in cancer patients.  
 
The present Thesis is structured into five sections. 
1. Section 1 comprises Chapter 1 and Chapter 2.  
Chapter 1 describes the aims and the outline of the thesis. Chapter 2 consists of a general 
introduction reviewing the main concepts relevant to the studies’ design and analyses 
undertaken in the work ascribed to this thesis; specifically the multifactorial nature of cancer-
related malnutrition, its impacts on the patients’ disease progress as well as the interactions 
between nutrition, morbidity and Quality of Life.    
 
2. In Section 2, a pilot study conducted in a heterogeneous cancer patient population referred 
for radiotherapy is presented, which includes a critical analysis of different methods to measure 
QoL and the effect of nutritional intervention on nutritional parameters and QoL:  
• Chapter 3. Patients submitted to radiotherapy (RT), particularly of the head and neck or 
the gastrointestinal tract, are at higher risk of malnutrition, aggravated by the therapy 
induced toxicity that may further compromise nutrition and functional status. Since 
patients’ QoL reflects functional status, psychosocial well being, health perceptions and 
disease/treatment-related symptoms, the patients’ nutritional status, nutritional intake 
and symptoms are thus likely to assume a significant role in their QoL. We investigated: 
1) the patients’ nutritional status, nutrient intake and QoL at the onset and at the end of 
RT, 2) whether individualised nutritional counselling, despite RT-induced symptoms, 
was able to enhance nutrient intake over time and whether the latter influenced the 
patient’s QoL and 3) which symptoms may have anticipated poorer QoL and/or reduced 
nutritional intake. This study showed that in patients prone to develop nutritional 
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problems and to report the worst QoL during RT, an individualised nutritional 
counselling did improve nutritional intake which was identified as central to a better 
QoL. Additionally, from the two QoL instruments tested, the non-specific EUROQOL 
should be used routinely because its completion is less time consuming; the more 
comprehensive cancer-specific EORTC QLQ C-30 instrument covers more items and 
scales, identifies more domains and specific complaints, and although time consuming 
provides the accuracy required for research. Both instruments were able to assess 
patients’ QoL and both revealed the relevance of nutrition care. 
 
3. Section 3.  
• Chapter 4. Based on this background, gathering validated objective data on nutritional 
status and its evolution throughout the disease course is of prime concern. Thus, we 
conducted a prospective study in head and neck, oesophageal, stomach and colorectal 
cancer patients, aiming to explore the intricate construct of various disease-related and 
diet-related factors potentially implicated in the patients’ nutritional deterioration. The 
disease extent was hypothesized as key to current nutritional status, which was 
assessed by three different methods, further compared in order to disclose their 
reliability. Regardless of the nutritional assessment method used, nutritional depletion 
was a multifactorial outcome determined by cancer and diet-related factors, all of which 
were simultaneously evaluated in a general linear model. Advanced cancer stage 
showed by far the most significant association with worse nutritional status; cancer 
locations, duration of the disease, protein and energy intake, and previous surgery or 
chemotherapy, were also significantly associated. Besides the identification of valid 
nutrition assessment tools, this study provided novel clinical evidence of the complex 
interactions between cancer and/or treatment-related variables and diet modifications, 
all of which exerted a combined effect on the patients’ nutritional deterioration. Cancer 
location was the dominant factor influencing the pattern and/or progression of nutritional 
deterioration; though the tumour burden for the host was of major importance. Our 
results were consistent with the hypothesized relations between progressive disease 
and wasting, which purportedly exacerbate every organ/systemic physiological 
derangement.   
• Chapter 5. It then became necessary to explore the potential interaction(s) between 
various disease-related and diet-related factors likely to be implicated in the patients’ 
QoL. A prospective cross-sectional study was thus conducted in head and neck, 
oesophageal, stomach and colorectal cancer patients; the specific aims were to 
evaluate patients’ nutritional status, nutrient intake and QoL, taking into account the 
disease stage and previous therapeutic interventions, to determine the potential inter-
relations, and to quantify the relative impact of cancer/treatments and/or nutrition-
related factors on patients’ QoL. This study provided objective evidence that cancer, 
diet deficits, nutritional deterioration and therapeutic interventions are determinants of 
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the patients’ QoL, but with distinct relative weights. Whilst chemotherapy and surgery 
were perceived by the patients as of minor relevance, nutritional deficits and/or 
deterioration were intrinsic to the cancer location and stage, to reduced energy/protein 
intake and to weight loss, which were independent determinants of QoL. These results 
concur with seminal landmark data which revealed that semi-starvation impairs 
functional and psychological abilities, and in addition corroborated our previous study 
demonstrating the relationship between progressive disease and wasting.  
 
4. Section 4. Based on the knowledge that in the above mentioned cancer patients, the location 
and stage of the disease as well as nutritional aspects are major determinants of patients’ QoL, 
it remained to be proven whether nutritional intervention might influence outcomes; therefore 
two prospective randomised controlled trials of nutritional therapy were conducted: 1) in 
colorectal cancer or 2) head and neck cancer outpatients, in order to address the potential role 
of adjuvant oral nutritional support on patients’ outcomes.  
• Chapter 6. The study herewith summarised was designed to test the hypothesis of a 
causal pathway between nutritional therapy and functional/clinical outcomes. A 
prospective randomised controlled trial, in colorectal cancer patients referred for 
radiotherapy, was designed to investigate whether, and to what degree, total oral intake 
was affected by dietary counselling or ad libitum intake supplemented with commercial 
supplements, both provided during RT. Furthermore the impact of nutritional intake on 
predefined outcomes, nutritional status and QoL, during treatment and 3 months later 
was examined. Despite the expected and experienced detrimental effects of RT, 
concurrent nutrition care integrated in the overall patient management allowed proper 
assessment of nutritional status and nutritional requirements, dietary counselling, 
education and monitoring of diet compliance and timely management of symptoms. 
Nutrition intervention was central to the improvement of colorectal cancer patients’ 
nutritional as well as non-nutritional outcomes: nutritional intake and status, QoL and 
lessened morbidity even in the medium term. Adding oral nutritional supplements to the 
diet did not appear to be as effective as dietary counselling. The control group showed 
a progressive deterioration in all items. 
• Chapter 7. Within a similar framework, with the same goals and an identical study 
design as in Chapter 6, the results of a prospective randomised controlled trial of 
nutritional therapy in head and neck cancer patients, referred for radiotherapy, are 
presented. The results were similar to those registered in colorectal cancer patients: 
nutritional counselling was indeed central to the improvement of a diversity of patient 
outcomes in such patients: nutritional intake, nutritional status, QoL and lessened 
morbidity, even in the medium term, after treatment completion. Adding oral nutritional 
supplements to the diet did not appear to be as effective as dietary counselling. Indeed, 
concurrent individualized dietary counselling based on regular foods, was the most 
effective means of improving patients’ nutritional intake, status and QoL during RT 
 12
which are sustained 3 months after its completion, thereby lessening RT induced 
morbidity. The control group showed a progressive deterioration in all items. 
 
5. Finally, Section 5 comprises Chapter 8 in which results of the studies ascribed to this thesis 
are discussed and some guidelines for potential future research are also suggested. 
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SUMÁRIO 
O cancro é causa major de morte e morbilidade a nível mundial. É a segunda causa de 
morte mais frequente, e a mais importante em populações cada vez mais idosas, uma vez que 
a maioria dos tumores são diagnosticados em indivíduos mais velhos; de notar que a 
malnutrição associada ao cancro é causa de morte em 20% dos doentes. Apesar de cancros 
de diferentes tipos e localizações anatómicas determinarem padrões nutricionais diferentes, 
existe enorme discrepância entre estudos quanto à avaliação do estado nutricional e variáveis 
associadas à doença oncológica e/ou decorrente do(s) tratamento(s). É de há muito necessária 
uma análise aprofundada das potenciais interacções entre estas variáveis, com o objectivo de 
gerar evidência científica que justifique a integração de adequada terapêutica nutricional nos 
cuidados prestados ao doente. Adicionalmente, embora a prevalência da malnutrição em 
doentes oncológicos seja de 8 a 84%, e estando associada a limitações da capacidade 
funcional, a interacção entre estado e ingestão nutricionais, sintomas e outros factores 
associados à doença/tratamento(s) é uma combinação complexa que pode determinar a 
Qualidade de Vida (QV) destes doentes. No entanto, a multiplicidade de interacções entre o 
tumor, sua localização e estadio, tratamentos, estado e intervenção nutricionais, morbilidade e 
QV nunca foi explorada de forma sistemática. A evidência que consubstancia estas interacções 
será demonstrada na presente tese, que resulta da compilação de resultados obtidos em 
diversos estudos prospectivos realizados com doentes oncológicos.  
 
A presente Tese está estruturada em cinco secções. 
1. A Secção 1 contém o Capítulo 1 e o Capítulo 2.  
O Capítulo 1 inclui a descrição dos objectivos e o esquema do conteúdo temático desta tese. O 
Capítulo 2 consiste numa introdução geral que engloba uma revisão dos principais conceitos 
relevantes para o desenho e análises realizados nos estudos que dão corpo a esta tese; em 
concreto, a natureza multifactorial da malnutrição associada ao cancro, o seu impacto da 
progressão da doença, bem como as interacções entre nutrição, morbilidade e Qualidade de 
Vida.    
 
2. A Secção 2 contém o Capítulo 1 no qual é apresentado um estudo piloto realizado numa 
população heterogénea de doentes oncológicos referenciados para radioterapia; nesse estudo 
é realizada uma análise crítica de diferentes métodos de avaliação da QV e o efeito da 
intervenção nutricional em parâmetros nutricionais e de QV:  
• Capítulo 3. Os doentes submetidos a radioterapia (RT), em particular a cancro da 
cabeça e pescoço ou tracto gastrintestinal, apresentam maior risco de vir a desenvolver 
malnutrição agravada pela toxicidade decorrente do tratamento, que pode ainda 
influenciar a sua alimentação e estado funcional. Porque a QV dos doentes reflecte 
vários aspectos que englobam: estado funcional, bem-estar psicológico, percepções 
relativas à sua saúde e a sintomas decorrentes da doença/tratamento(s), também o 
estado e ingestão nutricionais podem ter um papel significativo na QV de cada doente. 
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Neste estudo foram avaliados: 1) o estado e ingestão nutricionais e QV dos doentes no 
início e no fim da RT, 2) se o aconselhamento nutricional individualizado, apesar da 
sintomatologia decorrente da RT, seria capaz de melhorar a ingestão, e se esta 
melhoria viria a ter algum reflexo na QV dos doentes, e 3) quais os sintomas que 
pudessem antecipar uma pior QV e/ou redução da ingestão nutricional. Este estudo 
mostrou que, em doentes com maior probabilidade de vir a desenvolver problemas 
nutricionais e pior QV durante a RT, o aconselhamento nutricional individualizado 
melhorou a ingestão nutricional, identificada como fulcral para uma melhor QV. Para 
além disso, verificámos que dos dois instrumentos de QV avaliados, o instrumento 
inespecífico EUROQOL pode ser utilizado na rotina, uma vez que o seu preenchimento 
é menos moroso; porém, o instrumento mais abrangente e específico para doentes 
oncológicos EORTC QLQ C-30, engloba mais itens e escalas, identifica mais domínios 
e sintomas específicos e embora seja mais moroso, tem a precisão e rigor exigidos 
para uso em investigação. Ambos os instrumentos avaliaram eficazmente a QV dos 
doentes e ambos revelaram a relevância da terapêutica nutricional. 
 
3. Secção 3.  
• Capítulo 4. Com base nos resultados antes obtidos, a recolha e análise de dados 
objectivos e válidos sobre o estado nutricional e sua evolução no decorrer da doença 
oncológica passou a ser um objectivo necessário. Assim, realizámos um estudo 
prospectivo em doentes com cancro da cabeça e pescoço, esófago, estômago e 
cólon/recto com o objectivo de explorar a complexidade decorrente de vários factores 
associados à doença e/ou à nutrição, potencialmente implicados na deterioração 
nutricional dos doentes. O estadio da doença foi a hipótese levantada como tendo 
potencialmente maior influência no estado nutricional; este foi avaliado por três 
métodos diferentes, posteriormente comparados de forma a analisar a sua validade. 
Independentemente do método de avaliação nutricional utilizado, verificámos que a 
deterioração nutricional, “outcome” de natureza multifactorial, é determinada por 
factores associados ao tumor e a aspectos relacionados com a nutrição, quando todos 
os factores foram avaliados em simultâneo por método linear generalizado. O estadio 
avançado do tumor revelou claramente ter a associação mais significativa com um pior 
estado nutricional; a localização anatómica do tumor, a duração da doença, a ingestão 
calórica e proteica, e a cirurgia ou quimioterapia prévias, também estavam 
significativamente associadas. Para além da identificação de ferramentas de avaliação 
nutricional validadas, este estudo contém evidência clínica pioneira e reveladora das 
complexas interacções entre numerosas variáveis, não apenas associadas ao tumor 
e/ou tratamentos mas também a modificações na ingestão nutricional; todas, embora 
com pesos diferentes, exercem um efeito combinado na deterioração nutricional dos 
doentes. A localização do tumor foi o factor dominante a influenciar o padrão e/ou 
progressão da deterioração nutricional, mas o estadio avançado do tumor teve uma 
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importância major. Os nossos resultados foram consistentes com as relações 
anteriormente suspeitadas entre progressão da doença e deterioração nutricional, esta 
ultima com o potencial de agravar disfunções orgânicas/sistémicas e fisiológicas.   
• Capítulo 5. Tornou-se então necessário investigar potenciais interacções entre vários 
factores, relacionados com a doença e com a nutrição potencialmente associados com 
a QV dos doentes. Foi assim desenvolvido um estudo prospectivo transversal em 
doentes com cancro da cabeça e pescoço, esófago, estômago e cólon/recto. Os seus 
objectivos específicos consistiram em avaliar o estado e ingestão nutricionais e QV dos 
doentes, tendo em consideração o estadio da doença e intervenções terapêuticas 
prévias, de molde a determinar as potenciais inter-relações e quantificar o impacto 
relativo para a QV dos doentes, atribuível ao tumor/tratamentos e/ou factores 
associados à nutrição. Este estudo evidencia que o cancro, défices de ingestão, 
deterioração do estado nutricional e intervenções terapêuticas, são determinantes da 
QV dos doentes, apesar de terem pesos relativos distintos. Enquanto os doentes 
atribuiam uma importância minor à quimioterapia e cirurgia, os défices nutricionais e a 
deterioração do estado nutricional eram mais valorizados e intrinsecamente 
relacionados com a localização e estadio do tumor, com a reduzida ingestão calórico-
proteica e com a perda ponderal, factores determinantes e independentes da QV. 
Estes resultados, concordantes com anterior demonstração experimental irrefutável de 
que o semi-jejum prolongado compromete as capacidades funcional e psicológica, 
corroboram ainda o nosso estudo anterior ao demonstrarem a relação entre doença 
avançada e depleção nutricional.  
 
4. Secção 4. Tendo como base o conhecimento de que nos grupos de doentes oncológicos 
supracitados, a localização e estadio da doença bem como aspectos nutricionais são 
determinantes major da sua QV, permanecia a hipótese a testar de que forma a intervenção 
nutricional poderia influenciar diversos “outcomes”. Foram assim realizados dois ensaios 
clínicos prospectivos randomizados e controlados com terapêutica nutricional, 1) em doentes 
com cancro colorectal e 2) em doentes com cancro da cabeça e pescoço, de forma a estudar o 
potencial papel desempenhado pelo suporte nutricional oral adjuvante em diversos “outcomes”.  
• Capítulo 6. O estudo aqui resumido foi desenhado para testar a hipótese da existência 
de uma relação causal entre terapêutica nutricional e “outcomes” funcionais/clínicos. 
Este ensaio clínico prospectivo randomizado controlado de terapêutica nutricional, em 
doentes com cancro colorectal referenciados para RT, foi desenhado para investigar 
se, e de que forma, a ingestão oral total era influenciada por aconselhamento dietético 
individualizado ou por ingestão ad libitum suplementada com suplementos comerciais, 
ambos administrados apenas durante a RT. Foi também examinado o impacto da 
ingestão nutricional em “outcomes” pré-definidos, estado nutricional e QV, durante o 
tratamento e 3 meses após o seu terminus. Apesar dos esperados, e verificados, 
efeitos deletérios da RT, a intervenção nutricional integrada na abordagem terapêutica 
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global permitiu não só a avaliação do estado nutricional e necessidades dietéticas, mas 
também o aconselhamento e educação nutricionais, a monitorização do cumprimento 
das recomendações nutricionais, bem como a adequação atempada da nutrição 
conforme a sintomatologia. A terapêutica nutricional foi essencial para a melhoria de 
“outcomes” nutricionais e não-nutricionais em doentes com cancro colorectal, a saber: 
estado e ingestão nutricionais, QV e redução da morbilidade mesmo a médio prazo. A 
adição de suplementos orais à dieta não foi tão eficaz como o aconselhamento 
nutricional. Todos os itens sob avaliação pioraram significativamente no grupo controlo 
apenas com ingestão ad libitum. 
• Capítulo 7. Partindo de uma hipótese semelhante, com objectivos e desenho de 
estudo idênticos ao do Capítulo 6, apresentamos neste capítulo os resultados de um 
ensaio clínico prospectivo randomizado controlado com terapêutica nutricional em 
doentes com cancro da cabeça e pescoço referenciados para RT. Os resultados foram 
semelhantes aos verificados em doentes com cancro colorectal: o aconselhamento 
nutricional foi de facto essencial para a melhoria de uma diversidade de “outcomes” 
nestes doentes, a saber: estado e ingestão nutricionais, QV e redução da morbilidade, 
mantidos a médio prazo mesmo após o terminus do tratamento. O efeito da adição à 
dieta de suplementos nutricionais não foi tão benéfico como o aconselhamento 
nutricional. O aconselhamento nutricional individualizado baseado em alimentos 
correntes foi realmente a forma mais eficaz de melhorar o estado e ingestão 
nutricionais e a QV dos doentes durante a RT, melhoria que se mantém 3 meses após 
o fim do tratamento e com consequente redução da morbilidade decorrente da RT. 
Todos os itens sob avaliação pioraram significativamente no grupo controlo apenas 
com ingestão ad libitum. 
 
5. Por fim, a Secção 5 inclui o Capítulo 8 no qual se apresenta a discussão dos resultados dos 
estudos que formam esta tese, e são apontadas algumas linhas orientadoras e sugestões para 
investigação futura. 
 
 
 
 
 
 
 
 
 17
 
Section 1 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18
 
 
Chapter 1 
 
 
 
 
AIMS AND OUTLINE OF THE THESIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 19
AIMS  
The main goal of the present thesis is to contribute to the understanding and knowledge of 
the potential interactions between cancer-related variables, nutrition and Quality of Life. The 
underlying hypothesis to be tested, in sequential prospective studies, is that a multidirectional 
influence among those variables requires a thorough analysis in order to devise a scientific 
approach to a comprehensive multiprofessional patient management, and to assert the weight 
and role of a meaningful nutritional therapy. 
 
The pilot study, Section 2, Chapter 3, aimed to investigate:  
1. The patients’ nutritional status, nutrient intake and QoL at the onset and at the end of 
RT; 
2. Which symptoms may anticipate reduced nutritional intake and/or poorer QoL; 
3. Whether individualised nutritional counselling improved nutrient intake over time and 
whether the latter influenced the patients’ QoL. 
 
The studies undertaken for the evaluation of potential interactions between various clinical and 
nutritional variables are presented in Section 3.  
The aims of the study presented in Chapter 4 were to explore: 
1. The construct of various disease-related and diet-related factors potentially 
implicated in cancer patients’ nutritional deterioration;  
2. Different nutritional assessment methods in order to disclose their reliability in this 
setting.  
In the study presented in Chapter 5 we investigated: 
1. Patients’ nutritional status, nutrient intake and QoL, taking into account disease stage 
and previous therapeutic interventions;  
2. Potential interaction(s) between the various disease-related and diet-related factors 
likely to be implicated in the patients’ QoL; 
3. The quantification of the relative impacts of cancer/treatments and/or nutrition-related 
factors on patients’ QoL. 
 
The randomised controlled trials of nutritional therapy are shown in Section 4, Chapter 6 and 
Chapter 7, aimed to test the subsequent hypothesis: does nutrition influence outcomes, e.g. 
nutritional status, nutritional intake, radiotherapy-induced morbidity and Quality of Life? Specific 
questions triggering these studies were: 
1. Is there a causal pathway between nutritional intervention and functional/clinical 
outcomes? 
2. Does individualised dietary counselling or ad libitum intake supplemented by 
commercial supplements during RT, affect oral dietary intake, nutritional status and 
Quality of Life?  
3. What is the impact of nutritional intake on predefined outcomes during RT? 
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4. Does adequate nutritional intervention have the potential to modulate/lessen 
treatment induced morbidity? 
5. Is the latter impact on the various outcomes sustained at 3 months after the nutritional 
and RT treatment completion? 
 
OUTLINE OF THE THESIS 
The present Thesis is structured into five sections. 
Section 1 comprises Chapter 1 and Chapter 2.  
Chapter 1 describes the aims and the outline of the thesis. Chapter 2 consists of a general 
introduction reviewing the background concepts fundamental to the working hypothesis and 
relevant to the design and analyses of the undertaken studies.  
Section 2 consists of a pilot study on nutritional intervention and QoL evaluations, Chapter 3.  
Section 3 displays the results of the studies evaluating the multiple interactions between 
disease/treatment(s), nutrition and QoL, Chapters 4 and 5. 
Section 4 contains the randomised controlled trials of nutritional therapy, Chapters 6 and 7.    
Section 5 includes a global discussion of the data collected in the various studies, their 
relevance for clinical practice and quality of health care, and suggestions for future research, 
Chapter 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 21
 
 
Chapter 2 
 
 
 
 
GENERAL INTRODUCTION 
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I. MALIGNANCY 
 The word “cancer” is inclusive and comprises a wide range of different types of malignant 
tumours, which can develop in virtually every body tissue, thus determining diverse clinical 
manifestations [1]. In 2001, the total number of incident cancer cases in Europe, for both men 
and women, was 1,480,110 with a 5-year prevalence of 4,049,077 [2]. Cancer is a major cause 
of morbidity and mortality, being the second most frequent cause of death worldwide [2, 3]. 
However, the advances in early diagnosis and sophisticated modalities of treatments increase 
the possibility of cure, or at least prolong survival. It is thus expectable that most cancer patients 
will be ambulatory with a desirable “good” quality of life, the latter requires a patient-centred 
multiprofessional management; the potential added value of nutrition remains to be scientifically 
ascertained [4].  
 
II. THE NUTRITION SPECTRUM IN ONCOLOGY 
1. OVERVIEW OF MALNUTRITION IN PATIENTS WITH CANCER  
Cancer has been associated with protein-energy malnutrition, or simply malnutrition [5, 6]. A 
series of studies conducted in patients with cancer, between 1932 and 1974, highlighted the 
syndrome of nutritional wasting apparently multifactorial in nature [7]. Although many studies 
were undertaken in the early 20th century, publications in 1980s and 1990s showed that 
malnutrition is still an unsolved phenomenon. Indeed, estimates of the prevalence of 
malnutrition in specific groups of cancer patients range from 8% to 84% apparently depending 
on the cancer site, e.g. 80% in patients with gastrointestinal cancer [5, 8-14] and 70% in 
patients with head and neck cancer [15-18].       
Cancer related wasting is generally regarded as a physiological adaptation to stress: the 
body sacrifices large portions of the muscle mass to spare more immediate critical functions in 
visceral organs. There are however limitations to this adaptive response: contraction of the 
skeletal muscle mass leads to muscle weakness, decreased work tolerance and functional 
capacity [19]. On the other hand, the most frequent manifestation of malnutrition reported by 
cancer patients is weight loss [5], which when exceeding 10% is of particular clinical and/or 
prognostic significance, because weight loss of this magnitude in the setting of any illness may 
lead to significant increases in morbidity and mortality [4, 20]. At least some degree of weight 
loss has been registered in up to 75% of cancer patients prior to surgery, 57% prior to 
radiotherapy, 51% prior to chemotherapy and 80% of general cancer patients living in the 
community [4]. Despite the suggestion that the presence of malnutrition varies according to the 
cancer anatomic location, the likelihood that a cancer patient will sustain substantial weight loss 
is likely to be related to other factors, e.g. the agressiveness of the cancer (stage and 
histological characteristics), anti-neoplastic treatments (radiotherapy, chemotherapy, surgery), 
age, and intervening emotional factors such as depression [21]. 
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2. CANCER-RELATED ANOREXIA AND SYMPTOMS 
Overall in any disease, clinical practice suggests that loss of appetite is probably the most 
frequent cause of reduced food intake, deriving from both physical and psychosocial problems; 
hence, anorexia is a common contributor to wasting in cancer [4]. Particularly in patients with 
cancers of the head & neck and of the gastrointestinal tract, due to the mechanical dysfunction 
or concurrent treatments, the act of eating may incite a variety of adverse symptoms: pain, 
dysphagia, vomiting, diarrhoea, and therefore a “voluntary anorexia” translates the patients’ 
learned food aversions as a means of avoiding such symptoms [22]. Moreover, food aversions 
may be present unrelated to any other symptom and even before the establishment of the 
diagnosis [23]. In addition, the tumour mass alone may preclude adequate ingestion of food. On 
the other hand, the emotional adjustment associated with dealing with cancer is per se a 
precipitant of depression and anxiety, which are known contributors to anorexia [24].     
Nevertheless, anorexia is commonly present even in the absence of the above mentioned 
factors and may even be the presenting symptom of cancer [25]. In this setting, anorexia is 
thought to be largely due to the effects of cytokines released by macrophages and lymphocytes 
of the host, in response to the presence of the neoplasm [26]. In fact, in animal models, a highly 
reproducible degree of anorexia may be observed with the administration of Tumour Necrosis 
Factor-α (TNF-α) [27], Interleukin-1 [28] and Interferon-γ [29].       
 
3. TUMOUR BURDEN AND METABOLIC DYSFUNCTION 
In order to tackle nutritional deterioration, gathering objective data on nutritional status and 
its evolution throughout the disease course, appears to be of prime concern. So far, only a few 
studies have addressed this area of clinical research and did report weight loss either as the 
most frequent presenting symptom [30] or as a sign of advanced disease stage [31]. 
Notwithstanding that different cancer types or locations may display different nutritional patterns 
[32, 33], studies are inconsistent in what concerns the eventual relationship between nutritional 
status and cancer/treatment-related variables. Indeed, longstanding energy and substrate 
deficits have not been previously investigated nor adjusted by the patients’ cancer stage, 
though wasting and marked nutritional intake deficits have been hypothesised to be related to 
advanced disease [5, 15, 34-38]; all factors are prone to exacerbate every organ/systemic 
physiological derangements.  
Besides the tumour burden, symptoms and intake disturbances, cytokines may enhance 
metabolic dysfunction in various ways. Therefore a wide spectrum of alterations in protein, lipid 
and carbohydrate metabolism may occur in cancer, Table 1.  
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Table 1 Metabolic mediators potentially involved in cancer anorexia and wasting   
Mediator Wasting-related effects  
Tumour necrosis factor-α 
 
• In animal models, injection induces anorexia, weight loss and cachexia 
[27] 
• May increase resting energy expenditure [39] 
• In animal models, has hypothalamic effects in inducing anorexia [27] 
• Inhibits lipoprotein lipase [40] 
• Causes hypertriglyceridemia [41] 
• Depletes body fat stores [39] 
• Increases skeletal protein breakdown [42] 
• Increases synthesis of acute phase reactants [42] 
Interleukin-1 
 
• In animal models, injection induces anorexia, weight loss and cachexia 
[43] 
• May increase resting energy expenditure [44] 
• In animal models, has hypothalamic effects in inducing anorexia [43] 
• Causes similar effects on fat metabolism as TNF-α [28] 
• Causes similar effects on protein metabolism as TNF-α [28] 
Interleukin-6 
 
• Induces hepatic gluconeogenesis [45] 
• Increases synthesis of acute phase reactants [46] 
• Increases lipolysis [44]  
• Augments the effects of TNF-α on lipid metabolism -α [28] 
• Increases anorexia [47] 
Adapted from Mutlu et al. [42] 
 
3.1 Protein metabolism and lean body mass 
Skeletal muscle is the body compartment where most of the contraction of lean body mass 
occurs [48]. The overriding functional significance of this is underscored by the observation that 
the extent to which this compartment is diminished correlates with the likelihood of survival [49]. 
The decrease in skeletal muscle mass appears to be due to both a reduction in muscle protein 
synthesis and an increase in muscle protein degradation [50]. In cancer-related wasting, TNF-α, 
Interleukin-6, Interleukin-1 and Interferon-γ appear to play major roles in mediating the 
dissolution of skeletal muscle [42].  
 
3.2 Lipid metabolism and adipose tissue 
In the wasting associated with cancer, adipose tissue constitutes the major source of energy 
and a decrease in fat mass may be observed [48]. The net efflux of glycerol and fatty acids from 
adipose tissue that is observed in cancer wasting appears to be due to at least three factors: 1) 
increased lipolysis in adipose tissue, apparently mediated by TNF-α and lipid mobilising factor 
[41]; 2) a decrease in de novo lipogenesis in the adipose tissue, suggested to be mediated by 
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TNF-α and Interleukin-1 [45]; and 3) diminished activity of lipoprotein lipase [40]. The latter 
enzyme is necessary for the uptake of fatty acids from circulating lipoproteins and the 
diminished activity in cancer appears to be mediated by TNF-α, Interleukin-6 and Interferon-γ 
[40].   
 
3.3 Carbohydrate and energy metabolism  
The most commonly altered aspects of carbohydrate metabolism include increased rates of 
gluconeogenesis and glucose flux, and the development of some degree of impaired insulin 
secretion as well as insulin insensitivity. The latter induces impaired glucose utilisation in 
peripheral tissues and glucose intolerance [51]. Similar alterations in glucose metabolism are 
observed in any condition associated with a systemic inflammatory response and are thought to 
be due to TNF-α [52]. These changes contrast with weight loss unrelated to illness or cancer, 
where insulin sensitivity is maintained [53].  
 
 In summary, if not stopped and ideally reversed, cancer related wasting will progress and 
lead to what is known as cancer cachexia, a syndrome of progressive weight loss and asthenia, 
responsible for the death of 20% of the patients with cancer [54-56]. Cachexia does appear to 
be the end-result of reduced nutrient absorption [57], alterations in the appetite, taste and/or 
dietary intake [30], metabolic alterations [58] and cancer-related immune activation with 
cytokine release [59]. Table 2 summarises the possible causes of cancer related malnutrition.  
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Table 2 Possible causes of cancer related malnutrition 
1. Reduced food intake due to: 
• Deterioration in taste, smell and appetite, as a consequence of the tumour and/or therapy [42, 
60-64] 
• Altered food preferences/food avoidance/food aversion [63, 65-67] 
• Eating problems [8, 68] 
• Dysphagia, odynophagia or partial/total gastrointestinal obstruction [62] 
• Early satiety, nausea and vomiting [61, 62] 
• Soreness, xerostomia, sticky saliva, painful throat, trismus [63] 
• Oral lesions and oesophagitis [62] 
• Radiotherapy/chemotherapy induced mucositis [69] 
• Acute or chronic radiation enteritis during and after radiotherapy [70, 71] 
• Depression, anxiety [42] 
• Pain [42] 
 
2. Malabsorption due to atrophy of the small bowel mucosa, chemotherapy or radiotherapy [62] 
 
3. Metabolic disturbances [42, 62, 72] 
 
4. Humoral and inflammatory responses (e.g. increased or abnormal cytokine activity/production, 
excessive monocyte and macrophage activation, cancer-specific cachectic factors (Mutlu, 2000 
#940; Nitenberg, 2000 #941) 
Adapted from Stratton et al. [4]  
 
III. THE IMPACT OF MALNUTRITION 
Malnutrition has a diversity of effects, influencing every system of the body, yet it is important 
to highlight the fact that malnutrition is more than a decline of nutritional status. A prolonged 
inadequate intake of food results in metabolic, body composition, physical (functional) and 
psychosocial changes, i.e. a malnutrition status, which is itself a disease and may further 
increase the risk of disease [4, 73]; there is growing recognition that nutritional intake per se 
may be at least as important as body mass and structure in maintaining normal whole body 
function. Thus, nutritional intervention studies are necessary to investigate whether or not the 
provision of nutritional support can reduce or avoid the potential consequences of malnutrition.      
Regardless of the underlying mechanisms, cancer-related weight loss and nutritional wasting 
are multidimensional manifestations that worsen patients’ well-being [74], tolerance to 
antineoplastic therapies and prognosis [5, 15]. Specifically, weight loss decreases 
immunological responses to tumour cells [75] and resistance to infection [35], enhances 
susceptibility to postoperative complications [36, 37], and increases disability and overall cost of 
care [38].  
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The potential consequences of cancer related malnutrition with obvious clinical implications 
are listed in Table 3.  
 
Table 3 Potential consequences of cancer related malnutrition 
1.  Reduced muscle function [76]  
2. Reduced performance status after chemotherapy [5, 6]  
3. Lower general health, lower social functioning, lower outlook/happiness [6, 64]  
4. Tendency for greater depression, anxiety, insomnia in weight-losing patients [77] 
5. Higher prescription and consultation rates [78] 
6. Increased complications after surgery [13, 15]  
7. Increased need for reventilation after lung cancer surgery [79] 
8. Lower chemotherapy response rates [5, 6] 
9. Increased risk of chemotherapy-induced toxicity [6] 
10. Shorter duration of remission after chemotherapy [80] 
11. Increased mortality, especially in gastrointestinal cancer patients [8], after surgery [12, 13, 15, 79, 
81] or after chemotherapy [6] 
12. Shorter survival overall [17, 82], after surgery [37, 83] or after chemotherapy [5], and in non-small 
cell lung cancer [84] 
Adapted from Stratton et al. [4]  
 
1. THE FFECTS OF ACUTE AND CHRONIC FOOD DEPRIVATION IN THE PRESENCE OF  
MALIGNANCY 
1.1 Immunity 
A key deleterious effect of malnutrition in cancer is the potential to impair or reduce the 
competence of the host’s immune system, thus promoting a poorer outcome along with an 
impaired capacity to arrest and/or recover from the disease. Nevertheless, in cancer patients 
many other factors, apart from nutritional status, may influence immune function: among others, 
infection, inflammation, drug therapy, besides the disease itself which may directly influence 
immunological function [75, 85].  
Impairments in immune function associated with nutritional status have long been 
demonstrated in a variety of cancer patient groups: 
• Malnourished patients with inoperable carcinoma of the oesophagus [86]; 
• Malnourished patients with hepatocellular carcinoma [87]; 
• Patients with squamous-cell carcinomas of the head and neck displayed a highly 
significant positive correlation between nutritional status and circulating immune 
cells [35, 88]. 
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1.2 Physical activity 
In experimental conditions, both short term starvation (water only) as well as prolonged 
semi-starvation in healthy volunteers has been reported to reduce physical activity [89, 90]. In 
the landmark semi-starvation study of Keys et al, in which healthy subjects lost 25% of their 
body weight over 6 months, there was a reduction in both resting energy expenditure and 
physical activity [91]. Feelings of tiredness and lethargy can further contribute to impaired 
physical activity. Marked decreases in physical activity that occur in severe disease-associated 
malnutrition may predispose to increased morbidity, in parallel to a reduced capacity to maintain 
daily activities and undertake work [89].   
 
1.3 Psychological function 
Mental function may be influenced by nutrition in several ways. Starvation and partial food 
deprivation in adults lead to anxiety, depression and/or other mental changes, which may in part 
be associated with micronutrient deficiencies [92]. Cognitive function may also be adversely 
affected. In Keys’ et al study, healthy volunteers who underwent partial starvation for 24 weeks, 
resulting in loss of 25% of body weight had a concomitant increase in their depression score 
[91].  
 
IV. TUMOUR BURDEN, MORBIDITY AND QUALITY OF LIFE 
Since 1948, when the World Health Organisation defined “health as being not only the 
absence of disease and infirmity but also the presence of physical, mental and social well-
being” [93], Quality of Life (QoL) issues have become increasingly more important in research 
[94]. Hence Quality of Life was acknowledged as a valid outcome in the growing field of 
outcomes research to evaluate efficacy, cost-effectiveness, and net benefit of new therapeutic 
strategies [95]. QoL assessment is able to measure changes in physical, functional, mental and 
social health in order to evaluate the human and financial costs as well as the benefits of new 
interventions [95]. 
It should be widely recognised that psychosocial factors such as pain, apprehension, 
restricted mobility and other functional impairments, e.g. difficulty in fulfilling personal and family 
responsibilities, financial burden and cognition decline, must be included in the description of 
the personal burden of illness [96, 97]. Despite this conceptual knowledge, there still is 
considerable scepticism and resistance regarding measuring patients’ QoL [97, 98]. In general, 
health-related QoL can be considered as the gap between expectations of health and the actual 
experience of it [4, 96].  
 
1. PATIENTS’ PERCEPTIONS 
QoL assessment and, more specifically, “health-related QoL” refer to the physical, 
psychological and social domains of health, seen as distinct areas that are influenced by a 
person’s experiences, beliefs, expectations and perceptions [99-101]. QoL assessment aims to 
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measure general well-being based on objective and subjective changes in physical, functional, 
mental and social health [97, 102]. Different individuals have different health expectations, 
though in cancer patients we should bear in mind that when measuring QoL, individuals may be 
at different time points throughout their illness when measurements are made and expectations 
may change over time [103]. Figure 1 shows domains known to contribute to the patients’ QoL.      
 
 
 
 
 
 
 
 
 
 
Figure 1 Domains that contribute to the patients’ QoL [104]. 
 
Hence, accurate assessment of QoL provides important patient information to clinicians and 
investigators, particularly in oncology treatment and research [105]. A debilitated QoL status 
can jeopardise the ability or willingness of a patient to complete a treatment regimen [106]. QoL 
measurement may also assist in establishing a definition of response where any response may 
be difficult to quantify or where benefits may occur in the absence of conventional endpoints, 
such as measurable tumour shrinkage [107].   
 
2. NUTRITION AND THE MODULATION OF MORBIDITY AND QOL IN CANCER   
QoL depends on physical and psychological well-being, both of which can be influenced by 
nutrition [108]. Nevertheless, despite the suggested association between worse overall well 
being/morbidity and nutritional deterioration [109], the interaction between nutrition and QoL 
remains underestimated [110]. Fatigue, anorexia and emotional stress, so common in cancer 
patients, may further aggravate and likewise may be worsened by poor nutritional intake and/or 
QoL [103, 108]. Tumour location and symptoms, e.g. anorexia, taste changes, dysphagia, 
nausea, vomiting, diarrhoea, may further compromise nutrition and functional ability [30, 37, 
111]. Thus, the interaction between nutritional status and intake, as well as nearly all of the 
experienced symptoms, and/or disease/treatment-related factors, adds up to a complex 
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combination potentially capable of determining each patient QoL. Indeed, there is the 
suggestion that poor nutritional status may have an impact in QoL: good nutrition is essential for 
adequate function and survival, but eating per se encompasses other needs, including pleasure, 
satisfaction, conviviality and provision of a structure to the day [112].  
Moreover, it must be emphasised that the nutritional content of the patient’s diet, with 
appropriate dietary and food manipulations, may potentially improve nutritional intake as well as 
some symptomatic morbidity, derived either from the cancer itself and its anatomic location, or 
from anti-neoplastic treatments and/or surgery. Nutrition is known to influence various 
gastrointestinal tract functions, such as motility, enzyme secretion and nutrient absorption; 
likewise, nutrition modulates the gastrointestinal flora whose ecology is central to the 
pathogenesis of mucosal injury [113]. Another example is the modification or modulation of the 
oral cavity ecology, by means of stimulating salivary secretion, and thereby decreasing 
oral/oropharingeal/oesophageal intolerance to foods [114]. This overview depicts some 
evidence which supports nutrition as a major issue in QoL in the context of oncology, and that 
cancer patients should not be left to follow an ad libitum intake without adequate orientation.  
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ABSTRACT 
Purpose: To investigate in cancer patients referred for Radiotherapy (RT): 1) Quality of Life 
(QoL), nutritional status and nutrient intake, at the onset and at the end of RT; 2) whether 
individualised nutritional counselling, despite symptoms, was able to enhance nutrient intake 
over time and whether the latter influenced the patient’s QoL; 3) which symptoms may 
anticipate poorer QoL and/or reduced nutritional intake.  
Material and Methods: One hundred twenty five patients with tumours of the head-
neck/gastrointestinal tract (high-risk: HR), prostate, breast, lung, brain, gallbladder, uterus (low-
risk: LR) were evaluated before and at the end of RT. Nutritional status was evaluated by 
Ottery’s Subjective Global Assessment, nutritional intake by a 24hr recall food questionnaire 
and QoL by 2 instruments: EUROQOL and the European Organisation for the Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30.  
Results: Baseline malnutrition was prevalent in HR Vs LR, p=0.02; nutritional intake was 
associated with nutritional status, p=0.007; the latter did not change significantly during RT. In 
LR, baseline energy intake was higher than EER, p=0.001 and higher than HR’ intake, p=0.002; 
the latter increased, p<0.03 in spite of symptom increase anew and/or in severity, p=0.0001. 
According to both instruments, QoL was always better in LR Vs HR, p=0.01; at the end of RT, 
QoL improvement in HR was correlated with increased nutritional intake, p=0.001, both 
remained stable in LR. 
Conclusions: Individualised nutritional counselling accounting for nutritional status and 
clinical condition, was able to improve nutritional intake and patients’ QoL, despite self-reported 
symptoms.  
 
INTRODUCTION 
In cancer patients malnutrition is multifactorial and bears a negative prognosis (Cravo, 2000 
#492; Van der Schueren, 1999 #460). Patients submitted to radiotherapy (RT), particularly of 
the head and neck (HN) or the gastrointestinal (GI) tract, are at higher risk of malnutrition [Van 
der Schueren, 1999 #460]; therapy induced toxicity, e.g. mucositis, xerostomia, taste changes, 
odynophagia, dysphagia, nausea, vomiting, diarrhoea and anorexia may further compromise 
nutrition and functional ability (Cosnes, 1988 #461;Deitel, 1987 #462).  
Quality of Life (QoL) is a subjective multidimensional construct representing functional 
status, psychosocial well being, health perceptions and disease/treatment-related symptoms 
(Ferrell, 1996 #452). Each nutrition related factor, nutritional status, nutritional intake and the 
above mentioned symptoms are thus likely to assume a significant role in the patients’ QoL 
(Schneider, 2000 #456). Although nutrition management has been proposed as auspicious to 
cancer patients (Hunter, 1996 #373), to date there is no evidence-based data to support that 
concept.  
Within this framework, we investigated whether individualised nutritional counselling would 
improve patient’s outcomes, nutritional status and QoL in cancer patients undergoing RT. Our 
specific aims were to investigate: 1) the patients’ QoL, nutritional status and nutrient intake, at 
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the onset and at the end of RT; 2) whether individualised nutritional counselling, despite 
symptoms, was able to enhance over time nutrient intake and whether the latter influenced the 
patient’s QoL; 3) symptoms which may anticipate poorer QoL and/or reduced nutritional intake. 
 
 
MATERIAL AND METHODS 
Study Design and Patient Sample 
This study was designed as a prospective descriptive study to investigate outcomes of 
nutritional counselling initiated prior to RT and was approved by the University Hospital Ethics 
Committee. Between July 2000 and February 2001 all consecutive cancer patients referred to 
the outpatient Radiotherapy Department were considered eligible. Before the decision of RT 
planning, the medical staff registered the patients’ clinical variables, cancer location and TNM 
staging (8). Exclusion criteria comprised: terminally ill patients, renal failure 
(creatinine>532µmol/L), congestive heart failure and hepatic failure (bilirubin>21µmol/L). The 
cohort studied included 125 adult patients, age 63±11 (33-86) years, 83M:42F, proposed for RT: 
primary, adjunctive to surgery or with palliative intent. Patients with tumours of the HN and GI 
tract were, on the basis of the expected RT-induced GI symptoms, classified as high-risk 
patients whilst the remaining were considered as low risk. 
Data was recorded in individual sheets preconceived for statistical analysis.  
Study Measures 
Assessment of nutritional status as described, food intake and dietary advice were 
performed by a research dietician (PR), at the onset, after 2 weeks and at the end of RT. QoL 
was evaluated at the onset and at the end of RT.  
Nutritional Assessment. Nutritional status was assessed by Ottery’s Subjective Global 
Assessment (SGA), a patient-generated assessment tool validated for cancer patients [Ottery, 
1996 #464]. The first four sections address: weight changes, symptoms (anorexia, nausea, 
constipation, mucositis, vomiting, diarrhoea, xerostomia, pain), alterations in food intake and 
functional capacity. Components of metabolic stress: sepsis, neutropenic or tumour fever, and 
corticoesteroids, and physical examination: subcutaneous fat (triceps skinfold and at the level of 
the lower ribs in the midaxillary line), muscle bulk and tone in the temporal, deltoids and 
quadriceps areas, ankle/sacral oedema, or ascites are added. As a result, nutritional status is 
categorised in three degrees: normal, moderate and severe malnutrition. Symptoms and side 
effects determined by therapy toxicity were scored by using a standardised form [Rubin, 1988 
#715].  
Nutritional Requirements, Dietary Assessment and Counselling. Basal energy requirements 
were estimated by the World Health Organisation formula [WHO, 1985 #450], for men between 
18-30 yrs [64.4 × weight(kg) – 113 × height(m) + 3000], or between 30-60 yrs [19.2 × weight(kg) 
+ 66.9 × height(m) + 3769] and for women between 18-30 yrs [55.6 × weight(kg) – 1397.4 × 
height(m) + 146], or between 30-60 yrs [36.4 × weight(kg) + 104.6 × height(m) + 3619], or by 
the Owen et al formulas (>60 yrs) [Owen, 1986 #382; Owen, 1987 #383], for men [(879 + 10.2 × 
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weight (kg)) × 4.184] and for women [795 + 7.18 × weight (kg)] × 4.184]. These formulas were 
used due to their higher ability of predicting resting metabolic rate by comparison with the Harris 
and Benedict formula [Garrel, 1996 #451]. Height was copied from the patient’s Identity Card 
and weight was determined with a Jofre floor scale. Patient daily estimated energy 
requirements (EER) were calculated by multiplying basal requirements by a 1.2 activity factor 
[Food and Nutrition Board, 2002 #646]; protein requirements were estimated by comparison 
with reference values standardised for age and sex [Panel on Dietary reference values of the 
Committee on Medical Aspects of Food, 1991 #525]. 
Nutritional intake evaluation was derived from a 24hr-recall food questionnaire, the nutrient 
content was analysed by the DIETPLAN5 for Windows software (Forestfield software Ltd 2001, 
Horsham, UK). Individualised dietary advice was based on current foodstuffs, hence neither 
nutritional supplements nor enteral tube feeding were used. Nutritional counselling took into 
account each patient current food habits, actual nutritional status, calculated increase in energy 
and protein requirements to overcome deficits, known food aversions and reported symptoms. 
The latter were valued in the context of diet adequacy, which may determine variations in the 
patients’ daily meal plan, diet nutrient content, type and amounts of foodstuffs and food texture.  
QoL instruments. Quality of Life was evaluated in every patient by two methods in order to 
evaluate their relative performance given the significant differences in length of time ascribed to 
their completion. 
The EUROQOL instrument is non-disease-specific and describes and scores health states 
[Brooks, 1990 #368]. On its first part, health is defined in terms of five dimensions: mobility, self-
care, usual activities (work, study, housework, family, leisure), pain or discomfort and anxiety or 
depression. Each dimension is subdivided into three categories, which indicate whether the 
respondent has no problem, a moderate problem, or an extreme problem. Combinations of 
these categories define a total of 243 health states. On the second part, the respondent 
indicates his/her perception of his/her overall health on a visual analogue scale (0 denoting the 
worst imaginable health state and 100 the best imaginable health state).  
The European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire (EORTC-QLQ C30, version 3.0) is a 30-item cancer specific questionnaire 
including five functional scales (physical, emotional, cognitive, social, and role), three symptom 
scales (fatigue, pain, nausea/vomiting), a global health/QoL scale and six single items 
assessing symptoms and financial impact of disease [Aaronson, 1993 #503]. The raw scores 
were linearly transformed to give standard scores in the range of 0 to 100 for each of the scales 
and single items. Higher scores on the functional and global health scales indicated better 
functioning, whereas higher scores on the symptom scales represent more symptomatology.   
Statistical Analysis  
This study was based in the intention to treat principle. Target sample consisted of all 
consecutive cancer patients referred to the outpatient Radiotherapy Department included 
between July 2000 and February 2001. Sample size was determined by using the Neyman-
Pearson method REF E DETAILS. Based on the therapeutic intervention period, clinically 
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significant differences were assigned whenever nutritional intake adequacy was accomplished 
by meeting or overcoming the patients requirements, and an increase of 15-20% in QoL scores 
was acknowledged [Aaronson, 1993 #503]. Descriptive patient data concerning nutritional 
status and intake, symptoms and QoL are expressed as number and percentage, mean or 
median values and are presented for each diagnosis. In order to increase statistical power, 
patients were grouped as high (HR) or low-risk (LR). Continuous variables were logarithmically 
transformed before any parametrical tests were performed. Kruskal-Wallis analysis, the Mann 
and Whitney U test and Student’s t test were used to analyse associations and/or differences in 
QoL measures, nutritional intake or nutritional status between patient groups. Frequencies were 
compared by Chi-Square test. Spearman and Kendal Tau methods were used to determine 
correlations between nutritional intake or status and QoL dimensions. Multivariate logistic 
regression analysis was done to identify variables that influence nutritional intake and QoL. For 
all statistics, significance was accepted at the 5% probability level. SPSS 10.0 (Chicago, USA), 
EPI–Info 2000 (CDC, Atlanta, USA) and STATISTICA (Statsoft, Tulsa, USA) softwares were 
used for analyses. 
 
RESULTS 
Patients 
Patient’s diagnoses, tumour staging and RT treatment protocol are shown in Table 1.  
 
Table 1 Patient groups and treatment protocol  
Location n Staging  (n) Dose (Grays)/Fractionation (n)/ Days 
GI tract* 
    Oesophagus (OES) 
    Stomach (STO) 
    Colorectal (CR) 
 
6 
5 
46 
 
II (1); III (5) 
I (1); II (2); III (2) 
I (13); III (28); IV (5) 
 
45 / 25 / 33 
45 / 25 / 33 
50 / 25 / 33 
Head and neck* 
    Base of the tongue 
    Salivary gland 
    Tonsil      
    Nasopharynx 
    Oropharynx 
    Larynx 
 
3 
1 
2 
3 
3 
11 
 
IV (3) 
III (1) 
II (2) 
III (3) 
II (1); IV (2) 
I (1); III (3); IV (7) 
 
70-74 / 30-35 / 40-47 
70-74 / 30-35 / 40-47 
70-74 / 30-35 / 40-47 
70-74 / 30-35 / 40-47 
70-74 / 30-35 / 40-47 
70-74 / 30-35 / 40-47 
Prostate 21 II (15); IV (3) 50 / 25 / 33 
Breast 7 II (4); III (2); IV (1) 50 / 25 / 33 
Lung 5 II (2); III (2); IV (1) 50 / 25 / 33 
Brain 4 I (1); II (2); III (1) 50 / 25 / 33 
Gallbladder 6 II (1); IV (2) 50 / 25 / 33 
Uterus 2 II (1); III (1) 50 / 25 / 33 
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n=number of patients or radiation fractions; *defines high-risk (HR) patients due to the expected 
RT-induced symptoms; remaining diagnoses are classified as low-risk (LR). 
 
Nutritional Status 
Patients’ nutritional status categories at the onset and at the end of RT, according to the 
assigned risk level, are shown in Figure 1.  
 
 
Before RT, among HR group, only 1 patient with oesophageal cancer was well nourished, all 
patients with stomach cancer, 52% of HN cancer patients and 6 (13%) patients with CR cancer 
were malnourished; 6 (13%) patients with CR cancer were obese (body mass index >30 kg/m2); 
severe malnutrition was never observed in LR patients. Either at the onset or at the end of RT, 
malnutrition (moderate + severe) was more often present in the HR group, p=0.02. Nutritional 
status remained stable in all but one HN cancer patient whose moderate malnutrition 
deteriorated.  
At the onset and at the end of RT, only 1 of the LR patients reported diarrhoea and another 
anorexia. Throughout RT treatment, only in HR patients did symptoms increase, anew and/or in 
severity, p=0.0001. Figure 2 shows the number of patients presenting symptoms at the onset 
and at the end of RT in HR groups. No patients reported grade 3 or 4 symptomatology.  
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Figure 1 Nutritional status at the onset  and at the end of RT .  
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Nutritional Intake. Patients’ median energy intake and median estimated requirements (EER) 
are shown in Figure 3.   
 
 
At the onset, the median energy intake of LR patients was higher than their EER, p=0.001, and 
higher than the median intake of HR groups, p=0.002. In the latter, baseline median energy 
intake was lower then their EER, reaching significance only in CR and HN cancer, p=0.01. In all 
diagnoses baseline nutritional status was associated with nutritional intake, p=0.007 (Kruskal 
Wallis analysis adjusted by tumour staging). Despite the more severe symptoms in HR patients, 
energy intake did increase significantly, p<0.03, narrowing the gap with their EER; an 
improvement spontaneously attributed by patients to the individualised nutritional counselling. 
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Figure 2 Number of patients presenting symptoms at the onset  and at the end of RT  for HR 
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Patients with oesophageal and stomach cancer registered similar median increases of 275 kcal 
(200-425) and 280 kcal (185-400), respectively, a lower increment than in colorectal and HN 
patients: 410 kcal (352-545) and 510 kcal (358-785), respectively, p=0.03. In the LR group there 
was a median increase of 70 kcal (NS). Baseline protein intake was similar to requirements in 
LR patients and higher than in HR patients, p=0.003; in the latter, intake was lower than 
requirements (NS). Subsequent to counselling, protein intake did increase only in HR patients, 
p=0.08. 
QoL. The number (percentage) of patients that reported moderate or extreme problems 
regarding each EUROQOL dimension, at both evaluation set points, are summarised in Table 
2. 
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Table 2 Patients reporting problems in each EUROQOL dimension at the onset and at the end of RT 
EuroQoL  Problem 
Dimension  Moderate  Extreme 
  OES STO CR HN LR  OES STO CR HN LR 
  Onset End Onset End Onset End Onset End Onset End  Onset End Onset End Onset End Onset End Onset End 
Mobility  1 (17) 0 0 0 10 (22) 4 (9) 7 (30) 2 (9) 2 (4) 2 (4)  0 0 0 0 7 (15) 0 4 (17) 1 (4) 1(2) 1 (2) 
Self care  1 (17) 1 (17) 0 1 (20) 3 (7) 3 (7) 7 (30) 7 (30) 0 0  1 (17) 0 0 0 2(4) 2 (4) 5 (22) 5 (22) 0 0 
Usual activities  3 (50) 1 (17) 3 (60) 1 (20) 19 (41) 5 (11) 10 (43) 4 (17) 1 (2) 1 (2)  3 (50) 0 0 0 15 (33) 1 (2) 15 (52) 3 (13) 1(2) 1 (2) 
Pain/discomfort  2 (33) 4 (67) 1 (20) 4 (80) 7 (15) 23 (50) 3 (13) 10 (43) 3 (7) 3 (7)  0 1 (17) 0 1 (20) 1 (2) 20 (43) 1 (4) 12 (52) 2 (4) 2 (4) 
Anxiety/ 
Depression 
 2 (33) 1 (17) 1 (20) 1 (20) 20 (43) 5 (11) 11 (48) 4 (17) 4 (9) 2 (4)  1(17) 0 2 (40) 1 (20) 19 (41) 2 (4) 15 (52) 3 (13) 3 (7) 2 (4) 
 Data expressed as number (percentage) of patients.            
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    At any stage and for all cancer patients, impaired usual activities, pain/discomfort and 
anxiety/depression were the most common problems. Overall and for all QoL dimensions, HR 
patients presented worse scores than LR patients, either at baseline, p=0.001 or at the end of 
RT, p=0.01. Patients with oesophageal, stomach and head and neck cancer reported the worse 
QoL, in both evaluations. With the exception of pain/discomfort, all QoL dimension’ scores did 
improve in spite of RT, though only significantly in HR patients, p=0.004; pain/discomfort 
became worse throughout RT in association with more severe symptoms: anorexia (p=0.001), 
diarrhoea (p=0.002), dysphagia (p=0.01) and odynophagia (p=0.04). Nevertheless, nutritional 
intake was improved.  
In HR patients, worse mobility was associated with the presence of malnutrition, p=0.01 or 
reduced energy intake, p=0.0; usual activities were associated in a similar manner 
(p=0.02/p=0.03) as well as anxiety/depression, p=0.02/p=0.01. Additionally, multivariate 
analyses identified an association between worse nutritional status and worse mobility (p=0.03) 
or anxiety/depression (p=0.05), and flagged the association between anxiety/depression and 
nutritional intake (p=0.02). Nutritional intake improvement was identified as a major determinant 
of the QoL improvement registered at the end of RT, r=0.78, p=0.001. In LR patients, QoL 
dimensions were not significantly associated with any nutritional parameter.  
Figure 4 shows the mean self-rated health status (SRHS) on the visual analogue scale.  
 
 
 
 
 
 
 
At the onset, LR patients had a significantly higher mean SRHS when compared to HR patients, 
p<0.03. At the end, SRHS did increase in all patient groups, though significance was reached 
only in HR, p=0.01 Vs LR, p=0.06; oesophageal, stomach and HN patients reported the highest 
increase. In HR patients, baseline malnutrition was associated with lower SRHS, p=0.002 and 
at the end of RT, whilst improved nutritional status was associated with higher SRHS, p=0.03. 
Unlike LR patients, energy intake in HR was correlated with SRHS, both at the onset (r=0.47, 
p=0.001) and at the end of RT (r=0.32, p=0.005). At the end of RT, a multivariate analysis 
considering nutritional parameters and symptoms as the independent variables and SRHS as 
the dependent variable, highlighted its only association with nutritional intake, p=0.001. The 
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Figure 4 Patients’ mean self-rated health status at the onset  and at the end of RT . 
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increase registered in each patients’ nutritional intake was correlated with the increase of 
SRHS, r=0.72, p=0.001 indicating that the patients which improved their energy intake also 
enhanced their SRHS (Pearson’ method). 
The average rate of self-reported QoL problems evaluated by the EORTC QLQ C30 
instrument, at the onset and at the end of RT, is summarised in Table 3.  
 
Table 3 Self-reported QoL problems at the onset and at the end of RT 
Items  n=6 
OES 
 N=5 
STO 
 n=46 
CR 
 n=23 
HN 
 n=45 
LR 
  Onset End  Onset End  Onset End  Onset End  Onset End 
Function scales                
    Global QoL  52 69  56 70  68 75  50 73  73 80 
    Physical function  42 65  40 55  69 74  50 80  74 70 
    Role function  53 68  42 62  62 78  55 75  80 80 
    Emotional function  58 63  36 45  65 65  74 74  82 82 
    Social function  68 74  35 58  69 69  66 86  83 83 
   Cognitive function  54 65  41 55  38 58  53 72  80 80 
Symptoms, scales                
    Fatigue  59 64  29 19  26 26  67 52  30 30 
    Pain  22 58  29 52  25 49  13 60  17 17 
    Nausea and vomiting  25 45  24 72  48 58  43 18  4 4 
Symptoms, single items                
    Dyspnea  56 58  2 2  5 5  38 38  2 2 
    Sleep disturbance  45 45  35 35  39 39  53 53  21 21 
    Appetite  41 79  19 55  68 68  73 19  6 6 
    Constipation  2 2  1 1  15 4  8 8  12 12 
    Diarrhea  2 2  0 0  59 78  9 9  6 6 
    Finance  4 4  1 1  8 8  38 38  5 5 
 
At both evaluation set points, the overall QoL pattern was worse in HR patients, p=0.002; the 
worse dimensions were reported in patients with oesophageal, stomach and head/neck cancer. 
At the end of RT, in HR patients, function scales were improved (p=0.001) whilst a deterioration 
was reported for fatigue (NS), pain (p=0.003), nausea/vomiting (p=0.04) and appetite (p=0.001). 
In the LR group, global QoL was the only improved item, p=0.05. 
In HR patients baseline malnutrition was associated with worse function scales: global QoL 
(p=0.05), physical (p=0.01), role (p=0.02), cognitive (p=0.02), emotional (p=0.01) and social 
(p=0.01) as well as with symptoms: poor appetite (p=0.001) or increased fatigue (p=0.03) 
(Kruskal Wallis). All associations with function scales were also present at the end of treatment: 
global QoL (p=0.01), physical (p=0.02), role (p=0.02), cognitive (p=0.03), emotional (p=0.01) 
and social (p=0.04).  
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Baseline energy intake was correlated with function scales: global QoL (r=0.53, p=0.001), 
physical (r=0.26, p=0.02) and emotional (r=0.29, p=0.01) as well as with symptoms: anorexia 
(r=0.52, p=0.001) and fatigue (r=0.60, p=0.001). At the end of RT, energy intake was correlated 
with global QoL (r=0.50, p=0.001), physical (r=0.35, p=0.01) and emotional (r=0.38, p=0.01) 
functions. At the end of RT, a multivariate analysis considering nutritional parameters and 
symptoms as the independent variables and QoL dimensions as the dependent variables, 
nutritional intake was identified as the only variable associated with global QoL (p=0.001), 
physical (p=0.03), role (p=0.01) and emotional (p=0.04) functions, and pain/discomfort was only 
associated with increased severity of symptoms (p=0.001). The increase registered in each 
patients’ nutritional intake was correlated with the increase of global QoL (r=0.78, p=0.001), 
physical (r=0.68, p=0.002) and emotional (r=0.67, p=0.002) functions (Pearson’ method), which 
indicates that the patients which improved their energy intake also enhanced QoL dimensions. 
In LR patients, nutritional parameters were not significantly associated with QoL dimensions. 
 
DISCUSSION 
Nutrition is a key issue in oncology; nutritional decline ensues from the disease course and 
its treatment(s) [Cravo, 2000 #492;Van der Schueren, 1999 #460]. Although the clinical 
manifestations of radiation injury and its nutritional consequences have been well described 
[Chao, 1999 #505], to date there are no data on the role of routine adjuvant oral nutritional 
support in patients’ outcomes, e.g. nutritional status and intake or QoL. This prospective study 
provides evidence that early individualised nutritional counselling improves patients’ nutritional 
parameters and QoL.  
Malnutrition was prevalent amongst HR patients, oesophagus, stomach and HN cancer, and 
rare in LR patients, in whom severe malnutrition was never observed, thus stressing the major 
role of cancer location, as previously reported [Donaldson, 1984 #528; Liedman, 1999 #529]. 
Further on, the severity and extent to which patients experience side effects of RT depend on 
the tumour/treatment site, total dose, fractionation, volume of irradiated organ and injury repair 
mechanisms; high turnover cells, e.g. GI tract, are the most susceptible to acute radiation 
damage [Chao, 1999 #505]. In our study, RT-induced symptoms affecting nutrient intake, such 
as dysphagia, mucositis, xerostomia, taste changes, diarrhea, anorexia and nausea became 
evident only in HR patients. Our results corroborate that anorexia and nausea occur as a 
manifestation of the systemic tumour effect but their incidence increase dramatically as a 
consequence of RT [Mantovani, 2001 #511]. Albeit, although baseline nutritional intake in HR 
patients was significantly lower than EER it did increase significantly as a result of the 
individualised nutritional counselling (as patients spontaneously acknowledged), hence 
overcoming the previous energy deficit; only 2 of the LR patients reported diarrhoea or 
anorexia, intake remained adequate and stable. Both oesophageal and stomach cancer 
patients reported a similar increase of ±280 kcal, lower than the observed in CR and HN cancer 
patients, ±460 kcal, p=0.03. HR patients’ baseline protein intake was also lower than 
requirements (NS) and than LR patients’, p=0.003; nutritional counselling did improve protein 
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intake to a still inadequate amount (NS). These data support the concept of cancer patients’ 
aversion to protein dense foods, namely meat, further aggravated by RT [Mattes, 1992 #534]. 
Our results clearly show that individualised nutritional counselling based on each patient clinical 
condition, reported symptoms and nutritional status, is able to overcome the predicted 
deterioration subsequent to the increased severity of RT side effects; yet only HR patients 
appear to benefit.  
Besides the site-specific RT effects, patients experience fatigue, anorexia and emotional 
stress, which may influence nutritional intake and QoL [de Graeff, 1999 #532; Padilla, 1992 
#533]. QoL assessment measuring the patients’ experiences of the impact of disease/therapy, 
expectations and satisfaction should be the gold standard as an independent end-point in most 
clinical trials [Testa, 1996 #454; Wasserman, 1995 #466]. In the context of this prospective 
interventional study, we chose to test two QoL assessment instruments, in order to investigate 
their feasibility considering time of completion. Both, organised in distinct scales and items but 
somewhat covering similar dimensions, identified nutrition as one of the patients’ major worries, 
further emphasised by the associations between nutritional parameters and QoL. The 
EUROQOL instrument disclosed worse QoL in HR patients, namely oesophageal, stomach or 
HN cancer, both at baseline and at the end of RT, p=0.001. However, with the exception of 
symptom-induced pain/discomfort, and by contrast with LR patients, HR patients reported a 
significant improvement in all QoL dimensions at the end of RT. Although some data suggest an 
association between worse well being/morbidity and poor nutritional parameters [King's Fund, 
1992 #415], their relationship with QoL is widely underestimated [Vetta, 1999 #530]; two articles 
have addressed the value of artificial nutritional support on patients’ nutritional status and QoL 
[Van der Schueren, 2000 #459; Roberge, 2000 #510]. We have shown for the first time that, in 
HR diagnoses poorer nutritional status and intake were associated with worse mobility, limited 
usual activities and increased anxiety/depression. The improvement of the patient’s nutritional 
intake, was correlated with the reported improvement of QoL dimensions throughout RT. On the 
other hand, QoL dimensions scores were always much better in LR patients, likewise nutritional 
aspects were better, and not different, at both evaluation set points.  
Baseline mean self-rated health status (SRHS), i.e. the patients’ perception of their overall 
health [Brooks, 1990 #368] was also better in LR. Worse SRHS in HR patients was associated 
with poorer nutritional status and intake; although by univariate analysis, a better final nutritional 
status was associated with higher QoL, p=0.03, the use of multivariate analysis disclosed the 
single significant association between final SRHS and nutritional intake, p=0.001. Moreover, in 
spite of marked RT-induced symptoms, all HR patients did show a significant increase in their 
SRHS, which was correlated with improved nutritional intake, p=0.001. In LR patients, the slight 
SRHS improvement was independent of nutritional intake. Our findings in HR patients reveal 
that a successful nutritional counselling and monitoring play an important role in QoL 
maintenance and/or improvement.  
The EORTC instrument [Aaronson, 1993 #503] disclosed overall similar QoL results: HR 
patients self-reported worse QoL, more evident in oesophageal, stomach and HN cancer, when 
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compared with LR patients. At baseline, only in the HR group nutritional parameters did affect 
QoL components; malnutrition was associated with worse function scales as well as with poor 
appetite and increased fatigue. Poor scores in the latter two, along with worse global QoL, 
physical and emotional function scales were associated with low energy intake. At the end of 
RT, HR patients reported a higher QoL improvement, significant for all function scales, whilst LR 
patients only reported an increase in their global QoL without deterioration in any QoL 
dimension. HR patients worsened their symptom scales and single items, statistically significant 
for self-reported pain, nausea/vomiting and appetite; pain/discomfort was only associated with 
increased severity of symptoms (p=0.001). By multivariate analysis, nutritional intake 
improvement was the only variable associated with final global QoL (p=0.001), physical 
(p=0.03), role (p=0.01) and emotional (p=0.04) functions. As observed with the EUROQOL 
instrument, patients which improved their intake also enhanced their QoL dimensions.  
The results of both instruments showed that nutrition care does play a major role in the 
improvement of HR patients’ QoL, despite the expected detrimental effects of RT [de Graeff, 
1999 #532; Padilla, 1992 #533]. Our results agree with the Keys et al landmark study on human 
semi-starvation, which clearly demonstrated that psychological and functional improvements are 
early responses to nutritional intake increase [Keys, 1950 #629].  
The EUROQOL instrument describes health-related QoL according to 5 global domains; its 
completion is significantly shorter and less time consuming, on average 5±2 minutes. EORTC 
QLQ C-30 instrument covers more items and scales, identifies more domains and specific 
complaints, hence more comprehensive and time consuming, on average 13±3 minutes. Both 
instruments were able to assess patients’ QoL; in the context of this study both revealed the 
relevance of nutrition care. The EUROQOL instrument should be used as a routine in such 
patients, since Quality of Life is a major outcome (25, 26); the QoL instrument to use must be 
decided within the context of each clinical study/practice.  
Cancer patients are at nutritional risk to be evaluated by a health care professional with 
nutrition expertise (1). His/her integration in the multidisciplinary management allows a proper 
assessment of nutritional status and requirements, early nutritional counselling and monitoring 
of diet compliance enables timely adjustments according to symptoms. Our results show that, in 
patients prone to develop nutritional problems and to report the worst QoL, individualised 
nutritional counselling during Radiotherapy is feasible, does improve nutritional intake that is 
identified as central to a better QoL. Early intervention, sensible partnership with patients are 
the keys to success. 
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ABSTRACT  
Context: Undernutrition is a major source of morbidity and mortality in cancer patients.  
Objective: To evaluate the relative contributions of cancer staging/duration and diet on patients’ 
nutritional deterioration.  
Design: Prospective cross-sectional cohort study conducted from July 2000-February 2002.  
Setting: Ambulatory care. 
Patients: 205 (133M:72F) consecutive patients with cancer of the head-neck, esophagus, 
stomach, colon/rectum, age 53±12 (33-86) years, proposed for radiotherapy (primary, 
adjunctive to surgery, combined with chemotherapy or with palliative intent) were included. 
Clinical variables, nutritional status (%weight loss, Patient-Generated Subjective Global 
Assessment and body mass index), nutritional requirements, usual diet intake (Diet History) and 
current intake (24hr recall) were registered.  Results: In staging III/IV, there was a significant 
decrease of usual and current energy/protein intake (p=0.002), which was not observed in 
staging I/II. Nutritional intake reduction was influenced by disease duration (p=0.04), but when 
the latter was evaluated in a multivariate analysis, current diet intake was associated only with 
staging, p=0.004, thus disclosing a distinct pattern of nutritional intake between stages and 
diagnoses. By general linear model, advanced staging showed the most significant association 
with nutritional depletion (p=0.0001); significant associations were also found for tumor location 
(p=0.001), disease duration (p=0.002), nutritional intake (p=0.003), previous surgery or 
chemotherapy (p=0.02). Percentage weight loss showed a consistently superior performance 
regarding clinical variables and the ability to detect mild to extreme nutritional changes; relative 
to body mass index, Patient-Generated Subjective Global Assessment had a very high 
sensitivity/specificity and strong capacity of detecting patients at nutritional risk. 
Conclusions: Nutritional depletion is multifactorial, mainly dependent of the tumor burden for 
the host. Percentage weight loss is a sensitive and specific tool to effectively screen and identify 
malnutrition. Its joint use with Patient-Generated Subjective Global Assessment, which sets up 
boundaries for nutritional therapy, will optimize the efficacy of nutritional assessment and 
support in cancer patients. 
 
INTRODUCTION  
Cancer cachexia, a syndrome of progressive weight loss and asthenia, is the single most 
common cause of death in the patient with cancer1,2. Cancer cachexia appears to be the end-
result combination of reduced gastrointestinal nutrient absorption3, alteration in the diet or 
appetite4, hormone-induced metabolic changes5 and cancer-related immune activation with 
cytokine release 6. Regardless of the underlying mechanisms, cancer-related weight loss is a 
multidimensional manifestation that worsens the patients’ well-being7, tolerance to and 
prognosis after antineoplastic therapy8,9, decreases immunological responses to tumor cells10 
and resistance to infection11, and increases susceptibility to postoperative complications12,13, 
disability and overall cost of care14.  
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In order to tackle nutritional deterioration, gathering objective data on nutritional status and 
its evolution throughout the disease course appears to be of prime concern. So far, only a few 
studies have addressed this area of clinical research reporting weight loss either as the most 
frequent presenting symptom4 or as a sign of advanced disease staging15. Notwithstanding that 
different cancer types or locations may display different nutritional patterns16,17, there is some 
inconsistency between studies  relative to nutritional status assessment and cancer/treatment-
related variables; a thorough analysis of their interaction may step forward the eagerly awaited 
integration of appropriate nutritional therapy, as proposed by Ottery18.  
Within this framework, the major goal of this prospective study conducted in head and neck, 
esophageal, stomach and colorectal cancer patients, was to explore the intricate construct of 
various disease-related and diet-related factors potentially implicated in the patient nutritional 
deterioration. The disease extent, estimated by staging variables, was hypothesized as key to 
current nutritional status, which was assessed by three different methods, further compared in 
order to disclose their reliability. 
 
MATERIALS AND METHODS 
Study Design and Patient Sample 
The study was approved by the University Hospital Ethics Committee and was conducted in 
ambulatory patients with cancer of the head and neck, esophagus, stomach and colon/rectum. 
It was designed as a prospective cross-sectional study to investigate the role of disease staging 
and/or duration on the patients’ nutritional deterioration. All patients gave their informed consent 
to participate in the study. Between July 2000 and February 2002, all consecutive patients with 
cancer of the head and neck (HN), esophagus (ESO), stomach (STO) and colon/rectum (CR) 
referred to the outpatient Radiotherapy Department were considered eligible. Before the 
decision of radiotherapy planning, the medical staff registered, for each patient, the clinical 
variables, the duration of the disease, cancer location, the presence of distant metastases, and 
tumor burden according to TNM staging19, determined by local and hole-body imaging methods. 
The duration of the disease was defined as the length of time (in months) between symptomatic 
manifestations, later confirmed by histology, and study entry. The cohort included 205 adult 
patients (133M:72F), age 53±12 (range: 33-86) years, proposed for RT: primary, adjunctive to 
surgery, combined with chemotherapy or with palliative intent. Data was recorded in individual 
sheets preconceived for statistical analysis.  
Study Measures 
At the onset of RT, assessment of nutritional status was performed by a single trained 
research dietician (PR) as described. 
Nutritional Assessment. Height was measured in the standing position using a stadiometer 
and weight was determined with a Jofre floor scale. Nutritional status was assessed by: 1) 
calculating the percentage of weight loss by comparison with the patient’s usual weight, 
classified as severe if >10% in the previous 6 months; 2) Body Mass Index (BMI), classified as 
malnutrition if <20 kg/m2, normal if 20-25 kg/m2, overweight if 25 30 kg/m2 and obese if >30 
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kg/m2 20 and 3) Ottery’s Patient Generated Subjective Global Assessment (PG-SGA)21. The 
latter is a validated nutritional assessment tool for cancer patients, that addresses: a) weight 
changes, symptoms (anorexia, nausea, constipation, mucositis, vomiting, diarrhea, xerostomia, 
pain), alterations in food intake by comparison with the usual intake, and functional capacity; b) 
components of metabolic stress: sepsis, neutropenic or tumor fever, corticoesteroids, and c) 
physical examination: subcutaneous fat (triceps skinfold and at the level of the lower ribs in the 
midmaxillary line), muscle bulk and tone in the temporal, deltoids and quadriceps areas, 
ankle/sacral edema or ascites. Nutritional status is then categorized in three degrees: normal, 
moderate and severe malnutrition.  
Nutritional Requirements and Dietary Assessment. Basal energy requirements were 
estimated by the World Health Organization formula for subjects aged<60 yrs22 or by the Owen 
et al formulas for subjects aged>60 yrs23,24, given their higher ability to predict resting metabolic 
rate25. Patient daily estimated energy requirements (EER) were calculated by multiplying basal 
requirements by a 1.2 activity factor26; daily protein requirements were estimated by comparison 
with reference values standardized for age and sex, which ranged between 0.8 and 1.0 g/kg per 
day27. 
Usual (prior to the diagnosis) nutritional intake evaluation was derived from the diet history28 
and current intake was assessed by a 24hr-recall food questionnaire30. The nutrient contents of 
cooked foodstuffs and meals, were analyzed by the software DIETPLAN version 5 for Windows 
(Forestfield software Ltd 2002, Horsham, UK). 
In order to evaluate differences between cancer stages, patients were clinically and 
physiologically grouped in two classes: staging I+II (local disease) and staging III+IV (advanced 
local disease with or without lymph node invasion31.   
Statistical Analysis  
Statistical analysis was conducted using SPSS 10.0 (SPSS Inc, Chicago, USA) and EPI–Info 
2000 (CDC, Atlanta, USA). Patients’ disease staging and duration, nutritional status and intake 
were expressed as number and percentage, median and standard deviation values. Between-
group comparisons were performed by one way analysis of variance (ANOVA) for continuous 
variables, with Bonferroni or Dunn adjustment because of multiple comparisons; categorical 
variables were compared by Chi-square. Correlations were assessed by non parametric 
(Spearman) test. Multivariate general linear model was used to identify the variables that were 
significantly related with nutritional deterioration. Sensitivity and specificity of the nutritional 
assessment methods were compared by the Youden index which ranks diagnostic tests from –1 
(the worst) to 1 (the best).  
 
RESULTS 
Staging. Patient’s diagnoses and cancer staging are shown in Table 1 there were 35 staging 
I or II and 170 staging III or IV patients. 
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Table 1 Patient diagnosis and disease staging  
Location n Staging (n) 
Head and neck (HN) 
    Base of the tongue 
    Salivary gland 
    Tonsil    
    Nasopharynx 
    Oropharynx 
    Larynx 
 
7 
5 
5 
8 
15 
23 
 
IV (7) 
III (5) 
II (5) 
III (8) 
II (5); IV (10) 
I (5); III (3); IV (15) 
GI tract 
    Esophagus (ESO)  
    Stomach (STO) 
    Colorectal (CR) 
 
8 
20 
114 
 
II (1); III (4); IV (3) 
I (1); II (1); III (10); IV (8) 
II (17); III (72); IV (25) 
                 n= number of patients; none had distant metastases. 
 
 
Duration of the disease. Patients’ duration of disease was further grouped according to 
cancer staging, Figure 1. Overall, there was as a trend for patients with advanced disease 
staging to present longer duration of the disease, p=0.06.  
 
 
 
 
 
 
 
Figure 1 Duration of disease, shown as median and standard deviation, for each diagnosis 
grouped by tumor staging. The duration of disease was longer in staging III/IV patients Vs 
staging I/II patients, p=0.002. 
 
Nutritional intake. Both usual and current intakes were compared to estimated energy 
requirements (EER), taking into account disease location and staging, Figure 2. 
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In stage I/II patients, the median usual and current energy intake were not significantly different, 
unlike stage III/IV patients in whom there was a significant decrease of their usual intake, 
p=0.002. Furthermore, current energy intake was lower in stage III/IV patients than in staging 
I/II, p=0.001. 
Both usual and current protein intake were compared with the median reference value, taking 
into account disease location and staging, Figure 3. 
 
 
 
 
 
 
 
Usual and current protein intake were not significantly different in staging I/II patients, whereas 
staging III/IV patients presented a significant decrease of their usual intake, p=0.0001. Overall, 
current protein intake was lower in staging III/IV Vs staging I/II patients, p=0.001. Current 
nutritional intake was also affected by the duration of the disease, which was negatively 
correlated with energy, r=−0.31, p=0.04, and protein intake, r=−0.39, p=0.03. When the 
influence of disease staging and duration on nutritional intake were simultaneously analyzed, 
only staging revealed a significant association, p=0.004. Table 2 shows the median energy and 
protein intake decreases for each diagnosis and disease staging; energy intake decrease 
tended to be proportional to protein intake decreases, p=0.07, disclosing a global nutritional 
intake reduction. 
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Figure 2 Patients’ median estimated requirements , median usual energy intake  and median current energy intake . 
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Figure 3 Daily total protein intake in grams: patients’ median reference value , usual intake  and current intake . 
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Table 2 Median reduction in energy and protein intake  
Diagnosis Energy1  Protein2 
 Staging  Staging 
 I / II III / IV  I / II III / IV 
Head and neck − 40 − 908  − 0.5 − 92 
Esophagus − 52 − 1019  − 1 − 96 
Stomach − 20 − 451  − 0 − 62 
Colorectal − 20 − 648  − 0 − 67 
1Expressed as kcalories/day; 2expressed as grams/day. 
 
In staging III/IV patients protein intake was significantly lower than the reference values, 
p=0.001; but the decrease in energy intake, although significantly lower than the reference 
values (p=0.002), still remained within the estimated requirements. No reduction in energy and 
protein intake was found in staging I/II patients; further, their intake was significantly higher than 
the reference values, p=0.005. Staging III/IV patients with cancer of the HN or esophagus 
showed the worst decreases in both energy and protein intake, p=0.02. 
Nutritional Status  
Weight loss. For each diagnosis, patients’ median percentage of weight loss is shown in Figure 
4. 
 
  
 
 
 
 
 
 
 
Overall, weight loss was significantly higher in staging III/IV than in staging I/II patients, 
p=0.001. Amongst the latter, only 2/35 (6%) had lost more than 10% of their usual weight, 
whereas all staging III/IV patients reported weight losses greater than 10%. There was a trend 
for patients with >10% weight loss to have longer duration of the disease, p=0.08. When the 
influence of disease staging and duration on weight loss were simultaneously analyzed, only 
staging revealed a significant association, p=0.002. 
Body Mass Index. For each diagnosis, patients’ median BMI is shown in Figure 5. 
Figure 4 Median percentage of weight loss over the previous 6 months in staging I/II  and 
staging III/IV patients , according to disease location; HN: head-neck, ESO: esophagus, 
STO: stomach, CR: colorectal. 
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Overall, BMI was significantly lower in staging III/IV than in staging I/II patients, p=0.04. 
Amongst the latter, only 2/35 (6%) had a BMI below 20 kg/m2, which was observed in 45/170 
(26%) staging III/IV patients, p=0.05; further, 30 (26%) patients with CR cancer were still obese 
(20). No association was found between BMI and duration of the disease and further 
multivariate analysis of the latter with disease staging, revealed a significant association only 
between BMI and staging, p=0.05. 
Patient-Generated Subjective Global Assessment. Nutritional status according to disease 
location is shown in Figure 6. 
 
 
 
 
 
 
 
 
In staging I/II severe malnutrition was never observed, and only 4 patients (2 HN, 1 ESO and 1 
STO) presented with moderate malnutrition. Conversely, malnutrition (moderate+severe) was 
prevalent amongst staging III/IV patients (79%) relative to staging I/II (3%), p=0.003, and was 
not significantly associated with the duration of the disease, p=0.09. When the influence of 
disease staging and duration on nutritional status were simultaneously analyzed, only staging 
revealed a significant association, p=0.01. Categorization of numerical variables followed by 
concordance analysis disclosed a significant agreement between all nutritional assessment 
methods, k=0.34, p=0.01; percentage of agreement assigned to BMI was the lowest, k=0.12, 
p=0.06.  
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Figure 5 Median Body Mass Index for staging I/II  and staging III/IV patients , according to 
disease location; HN: head-neck, ESO: esophagus, STO: stomach, CR: colorectal. 
 
Figure 6 Nutritional status categories: normal nutritional status , moderate malnutrition  and 
severe malnutrition , according to disease location; HN: head-neck, ESO: esophagus, STO: 
stomach, CR: colorectal. 
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Current energy intake was not correlated with BMI (r=−0.17, p=0.24), but was significantly 
correlated with percentage of weight loss (Figure 7) and was also associated with nutritional 
status as categorized by PG-SGA (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
Patients with adequate nutritional status reported an energy intake ≥ 1500 kcal, corresponding 
to ±125% of the EER; on the other hand, in severely malnourished patients, energy intake was 
≤ 955 kcal, which corresponds to about ±80% of the EER.  
We further performed a sensitivity and specificity analysis (ROC curve interpreted by relative 
areas under the curves and Youden value) for each nutritional status assessment method. 
Because this is a comparative analysis of 1 or more methods Vs a standard, our results flagged 
percentage weight loss which showed a consistently superior statistical performance regarding 
clinical variables, as well as the ability of detecting mild to extreme nutritional changes. Figure 9 
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Figure 7 Correlation between % weight loss and energy intake, r=−0.67, p=0.002.  
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Figure 8 Energy intake by PG-SGA categories: normal , moderate malnutrition  and 
severe malnutrition ; a negative association was observed, p=0.003. 
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illustrates the sensitivity/specificity relation of % weight loss Vs PG-SGA and % weight loss Vs 
BMI. 
 
 
 
 
As for PG-SGA, the Youden value of 0.85, p=0.00001 (sensitivity=0.80, specificity=0.89) 
indicates a very high performance by comparison with the standard, and a strong capacity to 
effectively detect patients at high nutritional risk; in what concerns BMI, the Youden value of 
0.47, p=0.02 (sensitivity=0.27, specificity=0.27) indicates a poor performance by comparison 
with the standard, and a weak capacity to effectively detect patients at high nutritional risk. The 
influence of energy intake on nutritional depletion was further evaluated by non-parametric 
correlation stratifying on cancer staging (Figures 10 and 11). 
 
 
 
 
Figure 9 ROC curves for % weight loss Vs PG-SGA  and % weight loss Vs BMI .  
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Figure 10 Correlations between % weight loss and energy intake by cancer staging. Staging I : 
r=−0.14, p=0.09; II : r=−0.15, p=0.09; III : r=−0.52, p=0.002; IV : r=−0.72, p=0.001.  
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Figure 11 Associations between PG-SGA nutritional status categories and energy intake 
by cancer staging. Staging I : p=0.13; II : p=0.10; III : p=0.004;IV : p=0.003. 
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Cancer staging clearly disclosed a distinct pattern of nutritional deterioration between patient 
groups, thus highlighting the major contribution of advanced cancer staging. By adding cancer 
location to this analysis, we further found a distinct difference between diagnoses, Table 3. 
 
Table 3 Non-parametric correlation analysis between energy intake and nutritional depletion 
stratifying on cancer staging and corrected by diagnosis. 
Diagnosis  Staging 
  I II III IV 
Head-neck  r=−0.42, p=0.005 r=−0.48, p=0.004 r=−0.78, p=0.001 r=−0.84, p=0.001 
Esophagus  −* −* r=−0.89, p=0.0001 r=−0.91, p=0.0001 
Stomach  −* −* r=−0.88, p=0.0001 r=−0.90, p=0.0001 
Colorectal  r=−0.10, p=0.12 r=−0.14, p=0.09 r=−0.45, p=0.005 r=−0.53, p=0.002 
*Unable to compute the analysis due to small patient sample size. 
 
Advanced cancer staging was the common denominator to the patients’ nutritional depletion, 
clearly potentiated by the diagnosis. Patients with head-neck and esophageal cancers showed 
a markedly significant nutritional deterioration.  
By using a general linear model, using nutritional status as the dependent variable, the 
patients’ nutritional deterioration was related to the following variables: cancer staging, 
p=0.0001, location, p=0.001, duration of the disease, p=0.002, energy intake, p=0.003, protein 
intake, p=0.003, surgery, p=0.01 and chemotherapy, p=0.02. 
 
DISCUSSION 
Cancer-related nutritional deterioration is traditionally attributed to anorexia, continued loss 
of lean body mass, altered carbohydrate and lipid metabolism3-6; the latter may ensue from 
increased metabolic rates32, and the production and release of proinflammatory cytokines6. The 
progressive caloric deficit may be exacerbated by anorexia, disphagia, vomiting and 
malabsorption, associated with cancer itself and/or its treatment4,33,34. The relative contribution 
of the above conditions to nutritional depletion is thought to differ according to cancer type or 
site35,36, and has long been suspected to be proportional to cancer extent, a concept mostly 
based on clinical expertise and observational data15. The accurate longstanding energy and 
substrate deficit has not been systematically investigated nor adjusted by the patients’ disease 
staging.  
This prospective analysis of 205 patients with cancer of the head-neck and gastrointestinal 
tract, demonstrates for the first time that marked deficiencies in nutritional intake are 
conditioned by the extent of the disease. For all staging III and IV diagnoses, there was not only 
a significant decrease of the usual energy and protein intakes, p=0.002, but current intakes 
were also markedly lower relative to staging I/II patients, p=0.001. Although the global nutritional 
intake reduction was negatively correlated with the duration of the disease (p=0.04), which was 
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longer in advanced stages, by multivariate analysis only cancer staging was significantly 
associated with dietary changes.  
In order to further clarify the relative roles of nutritional intake reduction and cancer staging, 
the univariate associations between cancer-related variables, diet and nutritional depletion were 
investigated. Advanced staging was indeed the common denominator to the patients’ nutritional 
deterioration, by contributing to a worse nutritional status as well as disclosing a distinct pattern 
of nutritional intake between cancer stages. It should be stressed that cancer location further 
strengthened the association between advanced staging and depletion, and was simultaneously 
able to identify major differences between diagnoses; in fact, patients with head-neck and 
esophageal cancer were, already at early stages, severely depleted and showed significant 
dietary reductions.  
Severe nutritional deterioration has been reported in patients with cancer of the stomach, 
pancreas, lung and colon8. Although nutritional assessment is key to define nutritional 
status37,38, controversy exists regarding which is the most appropriate in a specific clinical 
setting. In this study we compared the widely used clinically significant weight loss, Ottery’s PG-
SGA (21) and body mass index39. In this study, BMI showed low sensitivity and specificity 
results, which indicate a poor performance and a limited capacity to effectively detect patients at 
high nutritional risk.  
It has become almost a dogma that unintentional weight loss higher than 10% of pre-illness 
weight, or in the previous 3-6 months, represents a high risk of malnutrition40-42. Our analyses 
corroborated its superior performance regarding all clinical variables, as well as its ability to 
detect mild to extreme nutritional changes; hence, weight loss was certainly the best indicator of 
nutritional deterioration and should be used to identify patients at nutritional risk or with recent 
onset undernutrition40-42. PG-SGA, a combination of weight changes, indicators of functional 
status, clinical aspects of nutritional intake and its impediments, determines nutritional risk and 
depletion21. Our results revealed high sensitivity and specificity for PG-SGA, indicating a very 
high performance and a strong capacity to effectively detect patients at high nutritional risk and 
malnutrition. In cancer patients, the PG-SGA should be used in conjunction with significant 
weight loss, aiming at establishing a planned overall cancer management  and set up 
boundaries to direct nutritional therapy18. This integration should be implemented in clinical 
practice, group protocols, and nutritional intervention clinical trials, in order to optimize quality of 
patient care.  
It is noteworthy that malnutrition was prevalent in staging III/IV Vs staging I/II patients, 
whether defined by a BMI below 20 kg/m2 (p=0.05), >10% weight loss in the previous 6 months 
(p=0.001), or according to PG-SGA (p=0.003); although some head-neck cancer patients were 
already malnourished at early stages, weight loss was never the presenting symptom.  
Regardless of the nutritional assessment method used in this study, we have shown that 
nutritional depletion is a multifactorial outcome determined by cancer and diet-related factors, all 
of which were simultaneously evaluated in a general linear model. Advanced cancer staging 
showed by far the most significant association with worse nutritional status; cancer location, 
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duration of the disease, protein and energy intake and previous surgery or chemotherapy were 
also significantly associated.  
Besides the identification of valid nutrition assessment tools, this preliminary study provides 
novel clinical evidence of the complex interactions between cancer and/or treatment-related 
variables and diet changes, all of which exert a combined effect on the patients’ nutritional 
deterioration. The pattern and/or progression  of nutritional deterioration is mostly determined by 
cancer diagnosis; albeit the tumor burden for the host appears to be of major importance. Our 
results are consistent with the hypothesized relations between wasting and progressive 
disease, which is likely to exacerbate every organ/systemic physiological derangement.   
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ABSTRACT 
Goals of work: 1) to evaluate Quality of Life (QoL), nutritional status and dietary intake taking 
into account the stage of disease and therapeutic interventions, 2) to determine potential inter-
relations, 3) to quantify the relative contributions of cancer/nutrition/treatments on QoL. Patients 
and Methods: In this prospective cross-sectional study conducted in 271 head-neck, 
oesophagus, stomach and colorectal cancer patients, the following aspects were evaluated, 
QoL (EORTC-QLQ C30), nutritional status (%weight loss over the previous 6 months), usual 
diet (comprehensive diet history), current diet (24hr recall) and a range of clinical variables. 
Main Results: Usual/current intakes differed according to the site of the tumour (p=0.02). Stage 
III/IV patients showed a significant reduction from their usual energy/protein intake (p=0.001), 
while their current intakes were lower than in stage I/II patients (p=0.0002). Weight loss was 
greater in stage III/IV vs I/II (p=0.001). Estimates of effect size revealed that QoL function 
scores were determined in 30% by cancer location, in 20% by nutritional intake, in 30% by 
weight loss, in 10% by chemotherapy, in 6% by surgery, in 3% by disease duration and in 1% 
by stage of disease. Likewise in the case of symptom scales, 41% were attributed to cancer 
location, 22% to stage, 7% to nutritional intake, 7% to disease duration, 4% to surgery, 1% to 
weight loss and 0.01% to chemotherapy. Finally for single items, 30% were determined by 
stage, 20% by cancer location, 9% by intake, 4% by surgery, 3% by weight loss, 3% by disease 
duration and 1% by chemotherapy. Conclusions: Although the cancer stage was the major 
determinant of the patients’ QoL globally, there are some diagnoses when the impact of 
nutritional deterioration combined with deficiencies in nutritional intake may be more important 
than the stage of the disease process. 
 
INTRODUCTION 
Malnutrition in cancer is likely to be multifactorial (1, 2), although tumour location and 
presenting symptoms, e.g. anorexia, taste changes, dysphagia, nausea, vomiting, diarrhoea, 
may further compromise nutrition and functional ability (2-4). The interaction between nutritional 
status and intake, and the above-mentioned symptoms and/or disease/treatment-related 
factors, is a complex combination which may dictate patients’ Quality of Life (QoL). 
 Quality of Life is a subjective multidimensional construct reflecting functional status, 
psychosocial well being, health perceptions and disease/treatment-related symptoms (5). 
Despite the suggested association between worse overall well being/morbidity and nutritional 
deterioration (6), the interaction between nutrition and QoL remains underestimated (7). 
Although nutritional care has been proposed as auspicious to cancer patients (8), to date there 
is scant evidence to support an interaction between nutrition and QoL.  
Within this framework, this prospective cross-sectional study conducted in head and neck, 
oesophageal, stomach and colorectal cancer patients was designed to explore the potential 
interaction(s) between various disease-related and diet-related factors likely to be implicated in 
such patients’ Quality of Life. Our specific aims were 1) to evaluate patients’ nutritional status, 
nutrient intake and QoL, taking into account disease stage and previous therapeutic 
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interventions, 2) to determine the potential inter-relations, and 3) to quantify the relative impact 
of cancer/treatments and/or nutrition-related factors on patients’ QoL. 
 
PATIENTS AND Methods 
Study Design and Patient Sample 
This prospective cross-sectional study, approved by the University Hospital Ethics 
Committee and conducted in accordance with the Helsinki Declaration of 1975 as revised in 
1983, was designed to investigate the inter-relations between cancer/treatment, nutrition-related 
factors and the patients’ QoL. Between July 2000 and September 2002, all consecutive 
ambulatory patients with cancer of the head and neck (HN), oesophagus (OES), stomach (STO) 
and colon/rectum (CR) referred to the Radiotherapy Department were considered eligible; only 
patients with other chronic diseases were excluded. All participants gave their informed consent 
to enter the study. For every patient and prior to radiotherapy planning, the medical staff 
registered: clinical variables, duration of the disease, cancer location, presence of distant 
metastases, and tumour burden according to TNM stage (9) determined by local and whole-
body imaging methods. The duration of the disease confirmed by histology, was defined as the 
length of time (in months) between symptomatic manifestations and study entry. In order to 
evaluate differences between cancer stages, patients were clinically and physiologically 
grouped in two classes: stage I+II (in situ or local disease) and stage III+IV (locally advanced 
disease with or without lymph node invasion and/or distant metastases) (10). Data were 
recorded on individual sheets pre-constructed for statistical analysis. 
Study Measures 
Nutritional Assessment. Weight was determined with a Jofre floor scale. Nutritional status 
was assessed by calculating the percentage of weight loss in comparison with the patient’s 
reported usual weight, and classified as severe when >10% had been lost over the previous 6 
months (11). 
Nutritional Requirements and Dietary Assessment. Basal energy requirements were 
estimated using the World Health Organisation formulae, patients aged ≤60 yrs (12) or by the 
Owen et al formulae, age >60 yrs (13, 14), given their better performance in predicting resting 
metabolic rate (15). To estimate patients’ daily energy requirements (EER), basal requirements 
were multiplied by a 1.5 activity factor (16); daily protein requirements were estimated by 
comparison with age and sex standardised reference values, which ranged between 0.8 and 1.0 
g/kg per day (16). 
Usual (prior to the diagnosis) nutritional intake was derived from a diet history (17, 18) and 
current intake was assessed by a 24hr-recall food questionnaire (19). The software DIETPLAN 
version 5 for Windows (Forestfield software Ltd 2003, Horsham, UK) was used to analyse 
nutrient contents of foodstuffs and meals. 
QoL instrument. The European Organisation for Research and Treatment of Cancer Quality 
of Life Questionnaire version 3.0 (EORTC-QLQ C30) was used in all patients to assess QoL. 
This instrument is a 30-item cancer specific questionnaire including 6 function scales (physical, 
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emotional, cognitive, social, role, and global health/QoL), 3 symptom scales (fatigue, pain, 
nausea/vomiting), and 6 single items assessing symptoms and the financial impact of the 
disease (20). Higher scores on the function scales indicate better functioning whilst higher 
scores on the symptom scales and single items denote increased symptomatology or worse 
financial impairment. Original scores were linearly transformed to obtain quantified scores within 
the range of 0 to 100; in addition, and for better validation in the clinical context, overall scores 
derived from function scales, symptom scales and single items, were calculated on the basis of 
the very high statistical significance of interscale correlations according to EORTC’s guidelines 
(20). 
Statistical Analysis  
Statistical analysis was conducted using SPSS 10.0 (SPSS Inc, Chicago, USA) and EPI–
Info 2000 (CDC, Atlanta, USA). Qualitative data, cancer location and stage, were expressed as 
number and percentage, while age, disease duration, weight loss, nutritional intake and QoL 
were expressed as median or mean and standard deviation. Between-group comparisons were 
performed by one way analysis of variance (ANOVA) for continuous variables, with Bonferroni 
or Dunn adjustment because of multiple comparisons; paired comparisons were performed by 
Students’ t test; categorical variables were compared by Chi-square. Correlations were 
assessed by non-parametric (Spearman) test. A multivariate general linear model was used to 
identify variables that were significantly related with the patients’ QoL. For all statistics, 
significance was accepted at the 5% probability level.  
 
RESULTS 
Patient sample. This study included 271 free-living patients (173M: 98F), mean age 54±12 
(range 32-87) years, referred for radiotherapy (primary, adjuvant to surgery, combined with 
chemotherapy or with palliative intent). Table 1 shows location and cancer stages: there were 
65 stage I/II and 206 stage III/IV. 
Table 1 Patients and disease stage   
Location n Stage  (number of patients) 
Head and neck 
    Base of the tongue 
    Salivary gland 
    Tonsil      
    Nasopharynx 
    Oropharynx 
    Larynx 
 
11 
6 
4 
11 
22 
33 
 
II (3); III (4); IV (4) 
II (1); III (5) 
II (4) 
II (2); III (9) 
II (5); IV (17) 
I (4); II (3); III (10); IV (16) 
Gastrointestinal tract 
    Oesophagus  
    Stomach  
    Colorectal  
 
14 
26 
144 
 
II (3); III (6); IV (5) 
I (2); II (4); III (11); IV (9) 
I (15); II (19); III (76); IV (34) 
                          n= number of patients 
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Duration of the disease was longer in stage III/IV (6±13 months) vs stage I/II patients (3.6±5 
months) (p=0.002). 
Nutritional intake. Both usual and current energy and protein intakes were respectively 
compared with EER and the protein median reference values, taking into account the disease 
location, Figure 1. 
 
 
 
 
 
 
 
 
 
 
In stage III/IV patients, the current protein intake was significantly lower than the reference 
value (p=0.001) whilst energy intake remained within the EER; conversely, in stage I/II patients, 
current energy/protein intake was still significantly higher than the reference, p=0.005. 
Moreover, current energy and protein intakes were lower in stage III/IV (p=0.0002 and p=0.001, 
respectively). Table 2 summarises the median intake reductions for each diagnosis and disease 
stage and shows that decreases in energy and protein intake followed a similar pattern and 
tended to be proportional (p=0.05). 
 
Table 2 Energy and protein intake: median reduction from usual intake 
Diagnosis Energy (kcal/day)  Protein (g/day) 
 Stage  Stage 
 I / II III / IV  I / II III / IV 
 n=65 n=206  n=65 n=206 
Head-neck (n=87) − 50 − 910  − 0.8 − 89 
Oesophagus (n=14) − 64 − 1095  − 1 − 94 
Stomach (n=26) − 25 − 491  − 0,2 − 64 
Colorectal (n=144) − 20 − 652  − 0,2 − 68 
n= number of patients 
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Figure 1 Panel A refers to energy and Panel B to protein intake; patients’ median estimated 
requirements , median usual intake  and median current intake ; HN: head-neck, ESO: 
oesophagus, STO: stomach, CR: colorectal. 
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The largest decreases, both in energy and protein intake, were shown in HN and OES stage 
III/IV patients (p=0.02). Stratified analyses further stressed the differences; stage III/IV patients 
reported a significant decrease from their usual energy (p=0.001) and protein intake (p=0.0002) 
contrarily to stage I/II patients.  
Nutritional status. The patients’ median percentage of weight loss for each diagnosis is shown 
in Figure 2; OES and STO cancer patients presented a higher percentage of weight loss 
compared with HN and CR patients, p=0.04. 
 
 
 
 
 
 
 
Figure 2 Percentage of weight loss over the previous 6 months (median) in stage I/II  and 
stage III/IV , according to cancer location; HN: head-neck, OES: oesophagus, STO: stomach, 
CR: colorectal. 
 
Overall, weight loss was significantly greater in stage III/IV relative to stage I/II patients, 
p=0.001. In the latter group, only 7/65 (10%) had lost more than 10% of their usual weight, 
whereas 175/206 (85%) of stage III/IV patients reported weight losses greater than 10%. 
Quality of Life. The median QoL dimensions’ scores are summarised in Table 3. 
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Table 3 QoL dimensions according to cancer location and stage  
Parameters  HN (n=87)  OES (n=14)  STO (n=26)  CR (n=144) 
  I/II III/IV  I/II III/IV  I/II III/IV  I/II III/IV 
Function scales              
    Global QoL  73 50  69 52  70 56  75 68 
    Physical  80 50  65 42  55 40  74 69 
    Activity  77 55  68 53  62 42  78 62 
    Emotional  64 51  63 51  45 36  65 65 
    Social   86 56  74 48  58 55  69 69 
    Cognitive  72 53  65 54  55 41  58 38 
Symptom scales             
    Fatigue  52 67  51 64  19 68  26 46 
    Pain  13 60  22 58  29 52  25 49 
    Nausea and vomiting  18 43  25 45  24 78  48 58 
Symptoms and single items             
    Dyspnea  18 25  38 56  2 2  5 5 
    Insomnia  23 53  25 45  25 35  19 39 
    Anorexia  19 73  41 55  19 79  28 68 
    Constipation  2 2  2 2  1 1  4 15 
    Diarrhoea  2 2  2 2  0 0  44 79 
Financial impact   38 38  4 4  1 1  8 8 
Results are expressed as median values; HN: head-neck, OES: oesophagus, STO: stomach, CR: colorectal; 
higher scores on the function scales indicate better functioning, higher scores on the symptom scales and single 
items denote increased symptomatoloy. 
 
There was a distinct pattern between diagnoses (p<0.03) in relation to the QoL function scales 
which were poorer in HN, OES and STO cancer (p≤0.008). Overall, symptom scales were 
worse in stage III/IV vs stage I/II, p<0.003; however, fatigue was significantly higher in HN and 
OES stage I/II than in STO or CR stage I/II (p=0.02), whereas nausea/vomiting was worse in 
stage I/II CR cancer (p=0.03) and pain was not significantly different between diagnoses. In all 
diagnoses, dyspnea, insomnia and anorexia were worse in stage III/IV vs I/II, p=0.002. 
Diarrhoea was more prevalent in CR cancer, p=0.001 and more severe in stage III/IV, p=0.03. 
Financial limitations associated with social/economical conditions were prevalent in HN cancer, 
p=0.002.  
The analysis of nutrition related factors and their relationships with QoL, showed that energy 
and protein intake were correlated with function scales: global QoL (r=0.53, p=0.001), physical 
(r=0.26, p=0.02) and emotional (r=0.29, p=0.01) as well as with some symptoms: anorexia 
(r=−0.52, p=0.001), fatigue (r=−0.60, p=0.001), pain (r=−0.55, p=0.003), nausea/vomiting 
(r=−0.51, p=0.003) and diarrhoea (r=−0.60, p=0.001). Malnutrition in these patients was 
associated with poorer function scales: global QoL (p=0.05), physical (p=0.01), role (p=0.02), 
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cognitive (p=0.02), emotional (p=0.01) and social (p=0.01) as well as with some symptoms: 
anorexia (p=0.001), increased fatigue (p=0.03), dyspnea, insomnia and diarrhoea (p=0.04).  
Given the strong interaction between QoL (dependent variable) and cancer stage and 
nutrition (independent variables), a non-parametric correlation analysis stratified by diagnosis 
was conducted. This analysis showed a distinct QoL pattern between diagnoses, and identified 
which variables were significantly associated with individual QoL global scores (Figures 3a, 3b, 
3c, 3d, in which the vertical axes denote the global scores of function, symptom scales and 
single items, derived from inter-patients’ median values). Figures 3a and 3b show that 
functional capacity for all diagnoses was significantly influenced by current nutritional intake 
deficit and recent weight loss, but it was not affected by the cancer stage; in both instances 
OES and STO cancer showed poorer global function scores relative to HN and CR, p=0.02. 
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Figure 3a Global function scores according to diagnoses stratified by quartile of energy and protein 
intake; the vertical axes denote the scores derived from inter-patients’ median values; HN: head-
neck, ESO: oesophagus, STO: stomach, CR: colorectal.  0-24%, p=0.003;  25-50%, p=0.01;  
51-75%, p=0.04;  76-100%, p=0.05.  
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Figure 3b Global function scores according to diagnoses stratified by categories of significant 
%weight loss; the vertical axes denote the scores derived from inter-patients’ median values; HN: 
head-neck, ESO: oesophagus, STO: stomach, CR: colorectal.  >10%, p=0.001;  5-10%, 
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 80
Figure 3c shows that global symptom scores were strongly associated with the stage of cancer 
and were not significantly different between diagnoses nor influenced by nutritional parameters. 
 
 
 
 
Figure 3d shows that, similarly to the global symptom scores, poorer global single item scores 
were only associated with stage III/IV; although there were no significant differences between 
HN, CR and OES cancer, the latter showed the worse single item scores by contrast to STO 
cancer, p=0.03. 
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Figure 3c Global symptom scores according to diagnoses stratified by cancer staging; the 
vertical axes denote the scores derived from inter-patients’ median values; HN: head-neck, 
ESO: oesophagus, STO: stomach, CR: colorectal.  IV, p=0.001;  III, p=0.002;  II, p=0.04;  
I, p=0.04.  
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Table 4 shows the results of a general linear model that included global QoL scores, 
nutritional parameters and cancer/treatment-related variables in order to calculate the estimates 
of effect size and the respective statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnoses
4,54,03,53,02,52,01,51,0,5
G
lo
b
al
 s
in
g
le
 i
te
m
 s
co
re
s
45
40
35
30
25
20
15
10
5
Staging
IV
III
II
I
HN OES STO CR 
Figure 3d Global single item scores according to diagnoses stratified by cancer staging; the 
vertical axes denote the scores derived from inter-patients’ median values; HN: head-neck, 
ESO: oesophagus, STO: stomach, CR: colorectal; IV+ III, p=0.001;  II+  I, p=0.05.  
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Table 4 Inter-relationships and estimates of effect size (relative weights) of nutritional parameters and cancer/treatment 
related variables on QoL: results from general linear model analysis 
 Global function scores  Global symptom scores‡  Global single item scores‡ 
Variable F-test Estimates of 
effect size* 
p  F-test Estimates of 
effect size* 
p  F-test Estimates of 
effect size* 
p 
Stage 1.6 1% 0.18  56.5 22% 0.001  103.7 30% 0.0001 
Location 111.2 30% 0.0001  77.2 41% 0.0001  49.2 20% 0.001 
Energy intake 27.2 10% 0.01  1.0 3% 0.35  3.9 4% 0.07 
Protein intake 27.2 10% 0.01  1.0 4% 0.25  4.2 5% 0.07 
Weight loss 133.7 30% 0.0001  0.05 1% 0.82  1.2 3% 0.10 
Duration of the disease 1.5 3% 0.14  10.0 7% 0.06  1.2 3% 0.30 
Chemotherapy 35.3 10% 0.001  2.1 4% 0.22  1.3 1% 0.25 
Surgery 6.1 6% 0.01  1.4 1% 0.86  3.0 4% 0.09 
Columns denote dependent variables, and rows independent variables; each of the scales and single items were linearly 
transformed and grouped to obtain global scores before inclusion in the analytical model; *the sum of percentages may 
not equal 100% due to the corrected error size; ‡due to the potential association between symptoms and diagnoses, 
associations were adjusted for cancer location. 
 
Cancer location, chemotherapy and surgery were significantly associated with all QoL scores 
whilst stage was only associated with symptom scores and single item scores. Nutritional intake 
and weight loss were significantly associated only with function scores, although there was a 
trend for an association with symptom scores and single items (p=0.06).  
In order to evaluate which diagnosis was most strongly associated with poorer QoL, 
individual dimensions were grouped and valued according to their relative weights. STO cancer 
patients had the worst QoL although not significantly different from OES cancer; HN and CR 
cancer patients had a better QoL (p=0.02), CR>HN (NS). Overall, the stage of disease was 
identified as the major determinant of the patients’ QoL (p=0.002), closely followed by 
deterioration in nutritional status (p=0.005) and dietary intake (p=0.007). 
 
DISCUSSION 
To be meaningful, QoL assessment must include the impact of the disease together with 
therapeutic interventions, expectations and personal satisfactions hence the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire was chosen 
as the most effective tool (20). The present study clearly shows that cancer patients’ QoL is 
multifactorial and that it is distinctively influenced by the disease, therapeutic interventions and 
various nutritional parameters. 
Cancer-related nutritional deterioration has been traditionally attributed to anorexia and 
metabolic derangements (3, 21, 22). Despite the fact that nutritional deterioration is associated 
with functional impairment (6), the interaction between nutrition and QoL is as yet unexplored 
(7). Artificial nutrition in cancer patients has been suggested to maintain nutritional status and 
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QoL (23, 24). Indeed, fatigue, anorexia and emotional stress, common in cancer patients, may 
further aggravate, but also be worsened by, poor nutritional intake and QoL (25, 26). 
This study focuses on the evaluation of the potential and relative weight of nutritional 
baseline data amongst other potential QoL determinants. In cancer, longstanding energy and 
substrate deficits were not previously investigated nor adjusted by the patients’ disease stage. 
Our results demonstrated marked nutritional intake deficits in the advanced stages of disease; 
there was not only a significant decrease from the usual energy and protein intake in stage 
III/IV, but current intakes were also markedly lower than in stage I/II. Stage III/IV HN and OES 
cancer were shown to be the most severe energy and protein depleted. 
An advanced stage of disease was, indeed, the common denominator of patients’ nutritional 
deterioration. Weight loss and reduced energy/protein intake were associated (p=0.06) although 
there was no consistent pattern. Our results corroborate and expand previous observations that 
progressive nutritional intake deficit may be associated with cancer location (3, 4, 27, 28), and 
may eventually be proportional to the extent of the disease (29).                                                                                                                                                                                                                                                                                              
In what concerns QoL dimensions, cancer stage mainly influenced the severity of symptom 
scales and single items, while energy/protein intake deficits and weight loss were detrimental to 
QoL function scales. Overall, patients’ functional capacity was affected by cancer location and 
nutritional factors with a similar quota of 40% each, and by the stage of disease in only 1%; the 
relative contributions ascribed to chemotherapy, surgery and duration of the disease were 10%, 
6% and 3%, respectively, as previously suggested in different patient groups (30-32). The 
symptom scales had an inverse pattern by comparison with function scales: 41% were 
attributed to cancer location, 22% to stage, 7% to nutritional intake, 7% to the duration of the 
disease, 4% to surgery, 1% to weight loss and 0.01% to chemotherapy. Likewise, cancer stage 
and location were the major determinants of QoL single items, which were worse in stage III/IV. 
Altogether, although the stage of disease was the major determinant of the patients’ QoL, in 
some diagnoses the impact of nutritional deterioration combined with deficient intake may be 
more clinically important.  
This study of 271 patients with cancer of the head-neck, oesophagus, stomach and 
colon/rectum, provides objective evidence that cancer, diet deficits, nutritional depletion and 
therapeutic interventions are determinants of the patients’ QoL, but with distinct relative weights. 
Whereas chemotherapy/surgery were viewed by the patients as of minor relevance, our data 
are consistent with the hypothesised relationship between wasting and progressive disease 
(29). Although nutritional deficits and/or deterioration were intrinsic to the site and stage of 
disease, reduced energy/protein intake and weight loss were independent determinants of QoL. 
Our results concur with Keys et al landmark study which showed semi-starvation to impair 
functional and psychological abilities (33). It is of clinical relevance that individualised nutritional 
counselling and education appears to effectively maintain/improve nutritional intake/status, 
along with a significant improvement in the patients’ overall QoL (34, 35). 
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ABSTRACT  
Purpose: To investigate the impact of dietary counseling or oral nutrition supplements on 
outcomes in cancer patients: nutritional, morbidity and Quality of Life (QoL), during and 3 
months after radiotherapy. Patients and Methods: 111 colorectal cancer outpatients referred for 
radiotherapy, stratified by staging, were randomized: G1(n=37) dietary counseling (regular 
foods), G2(n=37) protein supplements and G3(n=37) ad lib intake. Nutritional intake (diet 
history), status (Ottery’s Subjective Global Assessment) and QoL (EORTC-QLQ-C30) were 
evaluated at baseline, at the end, and 3 months after completion of radiotherapy. Results: At 
radiotherapy completion, energy intake increased in G1/G2 (p≤0.04), G1>G2 (p=0.001) and 
decreased in G3 (p<0.01). Protein intake increased in G1/G2 (p≤0.007), G1<G2 (NS) and 
decreased in G3 (p<0.01). At 3 months, G1 maintained nutritional intake, G2/G3 returned to 
baseline. After radiotherapy and at 3 months, anorexia/nausea/vomiting/diarrhea were higher in 
G3 (p<0.05). At radiotherapy completion, in G1 all QoL function scores improved proportionally 
to adequate intake/nutritional status (p<0.05); whereas in G2 only 3/6 function scores improved 
proportionally to protein intake (p=0.04) and in G3 all scores worsened (p<0.05). At 3-months, 
G1 patients maintained/improved function, symptoms, single item scores (p<0.02); in G2, only 
few function and symptom scales improved (p<0.05); in G3, QoL remained as poor as after 
radiotherapy. In G1/G2, respectively, improvement or deterioration of QoL correlated with better 
or poorer intake/nutritional status (p<0.003). Conclusions: During radiotherapy, both nutritional 
interventions positively influenced predefined outcomes, dietary counseling was of 
similar/higher benefit, whilst even 3 months after RT, it was the only method to sustain a 
significant impact on patient’ outcomes. 
 
INTRODUCTION 
Cancer related malnutrition is multifactorial (1) and bears a negative prognosis (2, 3). The 
risk of nutritional deterioration, particularly in cancers of the gastrointestinal tract, increases 
during radiotherapy (RT) (4). RT induced morbidity, e.g. anorexia, nausea, vomiting and 
diarrhea, is common and may compromise both nutrition as status and functional ability (5, 6), 
which in turn, impacts upon Quality of Life (QoL). The latter is a subjective multidimensional 
construct reflecting functional status, psychosocial well being, health and disease/treatment-
related perceptions (7, 8). Preliminary data support evidence-based benefits from oral nutritional 
intervention (9) and recently our group demonstrated the association between nutritional 
parameters and worse overall morbidity/QoL in cancer patients (10). 
This study was designed to test the hypothesis of a causal pathway between nutritional 
intervention and functional/clinical outcomes. Within this framework, we conducted a 
prospective randomized controlled trial in colorectal cancer (CRC) patients referred for 
radiotherapy. The study was designed to investigate whether dietary counseling or oral nutrition 
commercial supplements during RT affected oral intake. Furthermore the impact of nutritional 
intake on predefined outcomes (nutritional status and Quality of Life) during treatment and at 3 
months was examined.  
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PATIENTS AND METHODS 
This prospective randomized controlled trial was approved by the University Hospital Ethics 
Committee and was conducted in accordance with the Helsinki Declaration of 1975 as revised 
in 1983. All patients gave their written informed consent to participate in the study. Data were 
recorded on individual forms pre-constructed for statistical analysis. Between July 2000 and 
March 2003, all consecutive CRC ambulatory patients referred for RT were considered eligible, 
regardless of whether the proposed RT was primary, adjuvant to surgery, combined with 
chemotherapy or with palliative intent.  
For every patient and prior to RT planning, the medical staff registered the following: clinical 
variables, recent medications and chemotherapy, duration of the disease, cancer location, 
presence of distant metastases, and tumor burden according to TNM stage (11) determined by 
local and whole-body imaging methods. The duration of the disease, confirmed by histology, 
was defined as the length of time (in months) between symptomatic manifestations and study 
entry. Inclusion criteria were referral for RT treatment of 50.4 Gy administered in 28 fractions, 
absence of renal disease and/or diabetes mellitus. Throughout RT, all medication and 
concurrent chemotherapy was registered, and acute RT induced morbidity was scored from 0 to 
4 according to the EORTC/RTOG criteria, in which higher scores indicate increased symptom 
severity (12).  
Study Design 
A minimum sample size of 58 patients was calculated to detect a difference in body weight of 
1.9 kg, in nutritional intake of 25% and in QoL scores of 20% (that is, an effect size of 0.9) with 
a significance level of 0.01 between groups and a power of 0.85. Statistical power was based 
on the changes observed in weight, nutritional intake and QoL from a pilot study conducted in 
46 patients with CRC (13, 14). The present study therefore included 111 free-living patients 
(66M: 45F), mean age 58±15 (range 32-88) years: 45 in stage I/II and 66 in stage III/IV. All 
patients were referred for pre-operative RT combined with chemotherapy comprising 5-
Fluorouracil + Folinic Acid based regimens administered concurrently with the first and the last 5 
days of RT.  
Patients stratified by cancer stage were randomized at enrolment in permutation blocks of 
three, using a sequential series of numbered opaque sealed envelopes containing computer 
generated random assignments. A copy of the randomization sequence was kept separately 
from the study personnel. Randomization envelopes were opened before the first appointment 
with the patients by a person blind to the study procedures.  
Patients’ distribution after randomization was as follows: G1 (n=37) received individualized 
dietary counseling based on regular foods, G2 (n=37) were asked to consume two cans per day 
of a high protein liquid supplement in addition to their usual diet, in the control group G3 (n=37) 
patients were instructed to maintain their ad lib intake. Randomized patients had scheduled 
visits and identical contact time with the research dietician (PR). All parameters and study 
measures were assessed as described in Table 1 and the use of other medications and dietary 
supplements and compliance with dietary recommendations were monitored weekly. 
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Table 1 Data collection, nutritional intervention and visit schedule 
Visit Baseline RT treatment period End RT 3 months 
Study day 1 7 14 21 28 35 42 132 
Demography X        
Medical history X        
Informed consent X        
Randomization X        
Concomitant medications X X X X X X X X 
Nutritional status with PG-SGA X X X X X X X X 
Weight X X X X X X X X 
Diet history X       X 
24-hour recall  X X X X X X X 
RT induced morbidity with 
EORTC/RTOG 
  X X X X X X 
QoL with EORTC QLQ-C30 X      X X 
*Nutritional intervention (G1, G2) X X X X X X X  
Acceptability and compliance  X X X X X X  
*Nutritional intervention period from day 1 to 35. 
 
Overall, the main goal of both nutritional interventions was to enable every patient to achieve 
his/her calculated energy and protein requirements. Dietary counseling involved the prescription 
of a therapeutic diet using regular foods, which was further modified to provide for individual 
requirements. This was based on the need for an adequate intake and also took into 
consideration other relevant factors, including digestive and absorptive capacity, the need for 
alleviation or arrest of symptoms, and psychological factors. The therapeutic diet was 
additionally adjusted to the individual’s usual diet, thereby recognizing personal eating patterns 
and preferences, which formed the basis for individualized dietary counseling. The prescription 
identified the type, amount and frequency of feeding, specified the caloric/protein level to attain, 
together with any restrictions and limited or increased individual dietary components (15).   
Oral nutrition supplements, selected on the basis of the pilot study (13, 14) that identified 
protein as the main nutritional deficit, were ready to use, high protein, energy dense liquid 
polymeric formulations, intended to act as a supplement to the patients’ usual diet. Supplements 
were offered to patients who were able to select their preferred flavors and were instructed to 
use them as drinks in addition to any other meal. Supplements used throughout the study were 
always of the same commercial brand. Each 200 mL can provides 20g protein and 200 kcal. 
The amount of supplement provided was uniform, 2 cans/day and this covered the calculated 
requirements. Compliance was ensured by using a supplement consumption record which was 
kept daily by patients, and verified by a carer/relative.    
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Study Measures 
Nutritional Assessment was performed using 2 methods: 1) Ottery’s Patient Generated 
Subjective Global Assessment (PG-SGA) (16), a validated nutritional assessment tool for 
cancer patients that addresses: a) weight changes, symptoms (anorexia, nausea, constipation, 
mucositis, vomiting, diarrhea, xerostomia, pain), alterations in food intake by comparison with 
the usual intake, and functional capacity; b) components of metabolic stress: sepsis, 
neutropenic or tumor fever, corticosteroids, and c) physical examination: subcutaneous fat 
(triceps skinfold and at the level of the lower ribs in the midmaxillary line), muscle bulk and tone 
in the temporal, deltoids and quadriceps areas, ankle/sacral edema or ascites. Nutritional status 
was thus categorized in three degrees: normal, moderate and severe malnutrition. 2) 
Anthropometric data: height was measured in the standing position using a stadiometer and 
weight was determined with a Jofre floor scale. Body Mass Index (BMI) was then calculated 
according to the formula weight(kg)/height(m)2, classified as malnutrition if <20 kg/m2 or normal 
if ≥20 kg/m2 (17).  
Nutritional Requirements and Dietary Assessment. Basal energy requirements were 
estimated using the World Health Organization formulae for patients aged ≤ 60 yrs (18) or by 
the Owen et al formulae for patients aged > 60 yrs (19, 20), given their better performance in 
predicting resting metabolic rate (21). To estimate patients’ daily energy requirements (EER), 
basal requirements were multiplied by a 1.5 activity factor (22); daily protein requirements were 
estimated by comparison with age and sex standardized reference values, which range 
between 0.8 and 1.0 g/kg per day (22). 
Nutritional intake was derived from a diet history (23, 24); to assess changes in current 
intake during the RT treatment period a 24hr-recall food questionnaire was used (25). In detail, 
the primary source of the dietary data was Burke’s diet history, which was further complemented 
by multiple and sequential 24-hour recall evaluations (2 week-days and 1 weekend day) 
undertaken at every scheduled visit. Both energy and protein intakes were always analyzed 
together. The software DIETPLAN version 5 for Windows (Forestfield software Ltd 2003, 
Horsham, UK) was used to analyze nutrient contents of regular foods and meals. 
QoL instrument. QoL was assessed at the 3 time-points, always using the European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 
(EORTC-QLQ C30). This instrument is a 30-item cancer specific questionnaire including 6 
function scales (physical, emotional, cognitive, social, role, and global health/QoL), 3 symptom 
scales (fatigue, pain, nausea/vomiting), and 6 single items assessing symptoms and the 
financial impact of the disease (7). Higher scores on the function scales indicate better 
functioning whilst higher scores on the symptom scales and single items denote increased 
symptomatology or worse financial impairment. Original scores were linearly transformed to 
obtain quantified scores within the range of 0 to 100; in addition, and for better validation in the 
clinical context, overall scores derived from function scales, symptom scales and single items, 
were calculated on the basis of the very high statistical significance of the interscale 
correlations, which were calculated according to EORTC’s guidelines (7). 
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Statistical Analysis  
Statistical analysis was performed using SPSS 11.5 (SPSS Inc, Chicago, USA) and EPI–Info 
2000 (CDC, Atlanta, USA). All analyses were conducted on an-intention-to-treat basis, and 
therefore available data from all study patients were used. If any missing data were observed, 
the missing value(s) would be replaced by the average of the study group, which would have no 
effect on the estimators. Study groups were assessed for comparability at study entry. Data 
related to incidence, prevalence or frequency (symptoms, cancer stages and nutritional status 
categories) were expressed as number and/or percentage; age was expressed as the mean ± 
standard deviation (range); energy and protein intakes were expressed as the median (range), 
and patients’ QoL scores were expressed as median values. Continuous variables were 
analyzed using one-way analysis of variance (ANOVA) or Wilcoxon rank sum tests as 
appropriate; categorical variables and incidence, prevalence or frequency were evaluated by 
the Chi-square test. Univariate or multiple correlations were assessed by two-tailed non 
parametric Spearman tests. Statistical significance was set for a p value < 0.05. 
 
RESULTS  
As summarized in Table 1, all patients completed the study and none were lost to follow-up. 
Additionally, none were taking any other dietary supplements, either prior or throughout the 
period under scrutiny. 
Nutritional intake. At baseline, current energy and protein intakes for the three study groups 
were compared with EER and the protein median reference values. Patients’ median baseline 
estimated requirements and median nutritional intake were similar in all groups; energy intake 
tended to be higher than estimated requirements (0.07), protein intake was lower than reference 
values, p=0.06. Overall, energy and protein intakes were not significantly different between 
groups. The median nutritional intake patterns throughout the study are shown in Figure 1. 
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Figure 1 Energy and protein intake patterns during intervention and follow-up for the three study groups; G1=dietary 
counseling based on regular foods, G2=supplements, G3=ad lib intake. Energy: *G1>G2>G3 (p=0.002) and §G1>G2~G3 
(p=0.001); protein: **G1~G2>G3 (p=0.006) and §§G1>G2~G3 (p=0.001).  
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At the end of RT by comparison with the onset, energy intake showed a net increase of 555 
(398-758) kcal/d in G1 (p=0.002) and of 296 (286-401) kcal/d in G2 (p=0.04); G1>G2, p=0.001. 
Energy intake decreased in G3, 285 (201-398) kcal/d (p<0.01). At the 3 months follow-up, 
patients in G1 still complied with dietary recommendations as given during RT and maintained 
their energy intake, whilst in both G2 and G3 patients’ energy intake decreased (p=0.05) either 
to baseline (stage I/II) or below baseline (stage III/IV). There was a net increase in protein 
intake of 27 (20-35) g/d in G1 (p=0.007) and of 30 (20-40) g/d in G2 (p=0.001); intake in G1 
tended to be lower than in G2 (p=0.07); in both G1 and G2, the increase was always higher in 
stage I/II (p=0.05). Protein intake decreased in G3, 10 (7-15) g/d (p<0.01). At the 3 months 
follow-up, patients in G1 complied with nutritional recommendations as given during RT and 
maintained their protein intake, whilst both G2 and G3 patients decreased their protein intake 
(p=0.06) either to baseline (stage I/II) or below baseline (stage III/IV). 
Nutritional status. According to both PG-SGA and BMI, the prevalence of malnutrition at 
baseline was similar between the three study groups and was only observed in stage III and IV. 
At baseline, PG-SGA identified 15 malnourished patients in G1, 14 in G2 and 13 in G3, whereas 
BMI identified 5 malnourished patients in G1, 4 in G2 and 3 in G3. The number of patients that 
presented further nutritional deterioration both at the end of RT and at the 3-months follow-up 
was significantly higher in G2 and in G3 relative to G1 (p<0.001), using both methods. Similarly, 
nutritional deterioration was significantly more severe and incident in G3 relative to G1 and G2 
(p<0.008) again using both methods (Table 2). 
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Table 2 Changes in nutritional status during RT and at 3-months categorized according to PG-SGA and BMI  
Methods  G1  G2  G3  p1 p2 
  Decline  Maintained/improved  Decline  Maintained/improved  Decline  Maintained/improved    
  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months    
PG-SGA  3 10  34 27  19 24  18 13  34 36  3 1  <.002 <.001 
BMI  1 2  36 35  3 6  34 31  5 8  32 29  NS NS 
Data are expressed as number of patients; NS = not significant; p1 expresses the significance of statistical differences between intervention groups, regarding nutritional decline 
both at the End RT and at 3 months; p2 expresses the significance of statistical differences between intervention groups, regarding maintenance/improvement of nutritional 
status at the End RT and at 3 months 
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Considering PG-SGA specifically, 9/15 Group 1 malnourished patients at baseline improved 
their nutritional status, showing a net average recovery of 4 (2-7) kg at the 3 months follow-up. 
Conversely, none of the patients in G2 and G3 ever improved their nutritional status.  
Symptom induced morbidity. At the onset of RT, the prevalence of anorexia (≤9%), 
nausea/vomiting (≤8%) and/or diarrhea (≤17%) did not differ between the groups. After RT, 
more than 90% of the patients in the three study groups experienced RT induced toxicity, the 
severity and incidence of which are presented in Table 3. 
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Table 3 RT induced morbidity categorized according to severity grades (12) 
Symptoms  G1  G2  G3  p1 p2 p3 
  Grade 1  Grade 2  Grade 1  Grade 2  Grade1   Grade 2     
  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months     
Anorexia  20 6  13 1  19 5  14 3  17 12  17 10  <.02 <.01 <.001 
Nausea/ 
Vomiting 
 27 0  7 0  23 7  10 3  18 9  16 6  <.001 .17 <.0001 
Diarrhea  32 0  2 0  25 9  9 3  18 15  17 13  <.0001 <.05 <.0001 
Data are expressed as number of patients; grades 3 and 4 were never observed; p1 expresses the significance of statistical differences between intervention groups, regarding 
the reduction of grade 1 symptom’ incidence between the End RT and 3-months; p2 expresses the significance of statistical differences between intervention groups, regarding 
the reduction of grade 2 symptom’ incidence between the End RT and 3-months; p3 expresses the significance of statistical differences between intervention groups, regarding 
the reduction of grades 1+2 symptom’ incidence between the End RT and 3-months.  
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Further statistical analyzes showed that, overall, both at the end of RT and at 3 months, RT-
induced toxicity with symptomatic manifestations was higher in G3 (p<0.05). Conversely, G1 
showed the lowest symptom severity score (p<0.05). Furthermore, symptom incidence and/or 
severity improved differently in the three groups throughout the 3 months period between the 
end of RT and the follow-up visit. The incidence of grade 1+2 anorexia decreased in a similar 
fashion in G1 and G2, and was significantly better than in G3 (p<0.001). The significance of the 
reduction of grade 1+2 nausea and vomiting was distinctly different between groups: all patients 
improved in G1 vs 62% showing improvement in G2 vs 51% in G3 (p<0.0001). The incidence 
and severity of diarrhea was also significantly different between the groups: all patients 
improved in G1 vs 59% showing improvement in G2 vs 19% in G3 (p<0.0001). In the 3 groups 
the different symptomatology pattern occurred despite adequate and appropriate prescription of 
medications to alleviate symptoms. During RT, anti-emetic/pro-kinetic drugs 
(metoclopramide/domperidone) were prescribed for 5% of patients in G1, for 49% in G2 and for 
68% in G3. Whilst G1 patients no longer required these drugs, at 3 months, 10% of those in G2 
and 32% in G3 still needed them. The prescription of anti-diarrheal drugs (loperamide) was also 
significantly different between groups: during RT they were prescribed to 7% of patients in G1, 
to 53% in G2 and to 78% in G3. At 3 months, there was no need for loperamide in G1, but 15% 
of patients in G2 and 54% in G3 still needed it to control diarrhea. 
In order to clarify the influence of dietary intake and RT induced symptoms on patients’ 
nutritional decline, a two-tailed multiple correlation analysis was performed. In all study groups, 
dietary intake was not correlated with BMI (r≤−0.17, p≤0.24), but was significantly correlated 
with nutritional status as categorized by PG-SGA (r≤−0.59, p≤0.003).  Similarly, increased 
overall symptomatology was correlated with worse nutritional status as categorized by PG-SGA 
(r≤−0.63, p≤0.002), but not with BMI. 
Quality of Life. Median QoL dimension scores for the study groups at the three evaluation set 
points are presented in Table 4. 
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Table 4 Median Quality of Life dimensions’ scores. 
Items  G1  G2  G3 
  Onset End 3-months  Onset End 3-months  Onset End 3-months 
Function scales             
    Global QoL  48 75* 82#§  46 70* 62#  47 35* 30# 
    Physical function  49 74* 79#  48 65* 60#  45 25* 22# 
    Role function  50 78* 80#  52 65* 58  48 20* 19# 
    Emotional function  55 79* 83#  50 48 50  51 38* 28#§ 
    Social function  52 82* 85#  51 48 51  49 30* 26# 
   Cognitive function  64 73* 70#  62 62 54  62 55* 46#§ 
Symptoms, scales             
    Fatigue  30 55* 26§  31 75* 78#  29 78* 79# 
    Pain  25 63* 15#§  22 74* 30#§  23 78* 73# 
    Nausea and vomiting  15 50* 10§  14 71* 37#§  12 72* 68# 
Symptoms, single items             
    Dyspnea  5 8 8  6 7 13  5 6 15 
    Sleep disturbance  30 40* 29§  28 55* 75#§  32 60* 78#§ 
    Appetite  45 57* 48§  40 59* 72#§  42 65* 75#§ 
    Constipation  12 10 10  11 9 8  9 8 8 
    Diarrhea  38 45 39  35 81* 72#§  33 92* 78#§ 
    Finance  14 14 14  11 11 11  12 12 12 
 
 
 
 
 
 
At the end of RT in G1, despite RT induced symptoms (p<0.05), all QoL function scores 
improved significantly (p<0.002) and these were proportional to the increases registered in 
energy and protein intakes (r<0.089; p<0.001). There was also a linear positive association with 
the improvement in the patients’ nutritional status (p<0.05). In considering symptom scales and 
single items, pain worsened in association with anorexia (p=0.05), nausea/vomiting (p=0.04) 
and with diarrhea (p=0.03). In G2, only 3 function scores (physical, role and emotional) 
improved (p<0.05) and these were proportional to the increase in protein intake (p=0.04); the 
remaining function scales scores did not change significantly. Regarding symptom scales and 
Higher scores on function scales indicate better functioning, higher scores on symptom scales/single items denote 
increased symptomatology or worse financial impairment.     Highlights overall significant improvement,  
highlights overall significant deterioration,  highlights overall non-significant deterioration; *significant differences 
between baseline end of RT; #significant differences between baseline and at 3-months; §significant differences 
between end of RT and at 3-months.  
 100 
single items, worse fatigue and pain were associated with anorexia (p<0.001), nausea/vomiting 
(p≤0.04) and diarrhea (p<0.002); patients also reported increased severity of sleep disturbance 
(p=0.02). In G3 patients, all QoL function scores worsened in association with a deterioration of 
their nutritional intake (p<0.0001), as well as of their nutritional status (p<0.002). All symptom 
scales significantly worsened: increased fatigue was associated with poorer nutritional intake 
(p<0.003) and with nutritional status deterioration (p<0.001), pain worsened in association with 
nausea/vomiting and diarrhea (p<0.001); as far as symptoms and single items were concerned, 
sleep disturbance and appetite grew worse and were associated with nausea/vomiting and 
diarrhea (p<0.002).  
At 3-months follow-up and by comparison with the end of RT, all G1 patients maintained or 
improved their overall QoL (p<0.02), which was positively and proportionally associated with 
maintenance/improvement of nutritional status (p<0.02) and adequate dietary intake (p<0.01). 
Function scales scores also improved or were maintained (p<0.04), and symptom scales/single 
items were similar to baseline scores. G2 patients maintained or worsened their overall QoL 
(p<0.03) and patients also reported worse physical, role, emotional, and cognitive functions 
(p<0.05). This deterioration was associated with poor dietary intake (p<0.003) and depleted 
nutritional status (p<0.002). Notwithstanding the improvement of pain, nausea/vomiting and 
diarrhea (p<0.04), sleep disturbance and anorexia worsened (p<0.03), while the remaining 
scores were unchanged by comparison with the end of RT and were worse than at baseline. In 
G3, function scores further deteriorated both in relation to the baseline and to the end of RT 
(p<0.004). This deterioration was significantly associated with inadequate dietary intake 
(p<0.001) and deficient nutritional status (p<0.002). Symptom scale scores, apart from diarrhea, 
remained as poor as those reported at the end of RT, and were significantly worse than at 
baseline (p<0.001), the worst scores were associated with inadequate dietary intake (p<0.005).  
 
DISCUSSION 
Nutrition is a major issue in oncology and nutritional decline may ensue from both disease 
course and its treatment(s) (1). This carries a negative prognosis (2). Although symptomatic 
manifestations of radiation injury and their nutritional consequences have long been recognized 
(26), the potential role of adjuvant oral nutritional support on patients’ outcomes has not yet 
been explored. This prospective randomized controlled trial is the first to demonstrate that 
concurrent individualized dietary counseling, based on regular foods, is the most effective 
means of improving patients’ nutritional intake, status and QoL, thereby lessening radiotherapy 
induced morbidity.  
Weight loss during radiotherapy is an early indicator of nutritional decline (26). A 6-week 
course with ± 50 Gray of radiotherapy to the abdomen/pelvis, has been associated with an 
average weight loss of 3.4 kg, and 59% of the patients lost 10% of their baseline weight (27). In 
our trial and throughout the whole study period, including intervention and follow-up, nutritional 
deterioration was only observed in 18% of patients in Group 1 (dietary counseling), amounting 
to 50% in Group 2 (supplements) and to more than 90% of the Group 3 control patients. These 
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findings are concordant with the fact that disease-related malnutrition is frequently caused by 
reduced dietary intake (28). Indeed, although the three study groups showed comparable 
energy and protein intakes at baseline, nutritional intake patterns became quite different 
according to the type of nutritional intervention. At the end of radiotherapy, Group 1 showed the 
highest average energy intake sustained during the follow-up; the smaller increase in Group 2 
was lost at follow-up when energy intake decreased to/or below baseline, as was always the 
case in Group 3. During the nutritional intervention phase, both dietary manipulation and 
supplements were effective in restoring protein intake; similarly the increase was just 
maintained in Group 1 at 3 months, whereas in the other 2 groups the protein intake followed a 
pattern similar to that observed for energy (Figure 1). Thus, within the context of this clinical 
trial, individualized dietary counseling during radiotherapy, taking into consideration the patients’ 
clinical condition and symptoms, was the most effective nutrition intervention assuring a 
sustained and adequate diet which was able to overcome the predictable deterioration 
subsequent to radiotherapy. Moreover, such nutritional outcomes concur with what has been 
proposed as the causal pathway, i.e. optimizing nutritional intake may be the most effective 
method for treating disease-related malnutrition. There is evidence in a range of conditions to 
support the hypothesis that enabling the provision of the appropriate nutritional therapy leads to 
improved body weight and fat free-mass and that this generally reflects an improvement in 
protein-energy status (28).  
The severity and extent to which patients experience radiotherapy induced toxicity, depend 
on tumor histology, total dose, fractionation, volume of irradiated area, injury repair mechanisms 
and concurrent chemotherapy, which dictate susceptibility to acute radiation damage, during 
which high turnover cells of the intestinal tract are at higher risk (26). The resulting nutritional 
sequelae occur through direct effects on neoplastic and healthy tissues, which may induce 
anorexia, nausea/vomiting and diarrhea leading to physical discomfort and a variety of 
malabsorption syndromes (29-31). So far, the routine clinical approach is to maintain ad lib oral 
feeding, although comparative studies of functional, clinical and QoL outcomes which can be 
achieved via dietary manipulation or through oral nutrition supplementation, are lacking (28). 
Our study is the first to demonstrate that the nutritional content of the patient’s diet based on 
regular foods with appropriate manipulation, and not just protein and calorie supplementation, is 
the key to improving gastrointestinal function and other symptomatic manifestations during 
radiotherapy and in the medium term. In this trial, radiotherapy induced toxicity was more 
severe/incident in patients with an ad lib intake and to a lesser extent in the supplemented 
group, whereas in those patients who received dietary counseling and education, symptom 
incidence and/or severity were lower and their improvement in the medium term was faster 
(Table 3). Indeed, dietary modifications may alter bowel functions, such as motility, enzyme 
secretion and nutrient absorption (32); likewise, nutrition modulates the gastrointestinal flora 
whose ecology is central to the pathogenesis of radiation injury severity (33).  
QoL assessment measuring the patients’ experiences of the impact of disease/therapy, 
expectations and satisfaction should be the gold standard as an independent end-point in 
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clinical trials (34, 35). Patients experience functional limitations, cognitive alterations and 
emotional stress, and overall QoL depends on both physical and psychological well-being (7, 
36, 37). All these aspects may influence or be influenced by nutrition although the relationship 
between poor nutritional parameters and QoL remains widely underestimated (38, 39). Our 
group was the first to show that nutrition is a key determinant of QoL in cancer patients (10). In 
this clinical trial, both at the end and at 3 months after RT, dietary counseling (Group 1) 
significantly improved all QoL function scores in association with an adequate dietary intake and 
nutritional status. In patients who received oral supplements (Group 2), only 3/6 function scores 
improved during supplementation, and these were proportional to the increase in dietary intake; 
however, once the supplementation was discontinued most function scores deteriorated. 
Patients not submitted to any nutritional intervention (Group 3) experienced, throughout the 
whole study, a significant deterioration in function scores and fatigue in direct relation to the 
worsening of their nutritional intake and nutritional status. Therefore, our results emphasize that 
“the impairment in structure, function and well-being that form malnutrition, are nutritionally 
responsive” (28).   
Furthermore, the benefits of nutritional intervention on QoL were extrapolated to improved 
physiological function and overall clinical outcome. During radiotherapy, QoL symptom scales 
and single item scores deteriorated in all groups and these were significantly more pronounced 
in the ad lib group. These scales were also significantly worse in Group 2 vs Group 1. In the 
medium term, Group 3 symptom scales and single items remained as poor as those reported at 
the end of radiotherapy and worse than at the onset; worsening scores were again associated 
with inadequate nutritional intake. Conversely, in Group 1 patients all the above mentioned 
scales reverted to their baseline scores, whereas in Group 2 there was an improvement in pain, 
nausea/vomiting and diarrhea, although not as relevant as the improvement observed in Group 
1. These results in patients who experience persistent eating difficulties support the concept 
that increased intake of an appropriate mixture of nutrients using regular foods will be of major 
benefit in modulating outcomes.  
Despite the expected, and experienced, detrimental effects of radiotherapy, multiprofessional 
patient’ management allowed proper assessment of nutritional status and nutritional 
requirements, dietary counseling, education and monitoring of diet compliance and timely 
management of symptoms. Nutrition intervention was central to the improvement of colorectal 
cancer patients’ nutritional as well as non-nutritional outcomes: nutritional intake, status, QoL 
and lessened morbidity even in the medium term. Adding oral nutritional supplements to the diet 
did not appear to be as effective as dietary counseling. Early intervention and sensible 
partnerships with patients are key to success. 
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ABSTRACT  
Background: We aimed to investigate the impact of dietary counseling or oral supplements in 
cancer patients outcomes: nutritional, morbidity and Quality of Life (QoL), during and 3-months 
after radiotherapy. Methods: 75 head-neck cancer patients referred for radiotherapy were 
randomized: G1(n=25) dietary counseling with regular foods, G2(n=25) supplements and 
G3(n=25) ad lib. Nutritional intake (diet history) and status (Ottery’s Subjective Global 
Assessment), QoL (EORTC-QLQ-C30) were evaluated at baseline, end of radiotherapy and at 
3-months. Results: After radiotherapy, G1/G2 increased energy (p≤0.05) and protein (p≤0.006) 
intakes whereas both decreased in G3 (p<0.01). At 3-months, G1 maintained intakes, G2/G3 
returned to or below baseline. After RT, >90% patients experienced RT toxicity, not significantly 
different between groups with a trend for reduced syptomatology in G1 vs G2/G3 (p<0.07). At 3-
months, the reduction of incidence/severity of grade 1+2 anorexia, nausea/vomiting, 
xerostomia, dysgeusia was different: 90% of the patients improved in G1 vs 67% in G2 vs 51% 
in G3 (p<0.0001). After radiotherapy, QoL function scores improved (p<0.003) proportionally to 
improved nutritional intake+status in G1/G2 (p<0.05), and worsened in G3 (p<0.05); at 3-
months, G1 patients maintained/improved overall QoL which was maintained/worsened in 
G2+G3. Conclusions: During radiotherapy, both nutritional interventions positively influenced 
outcomes, counseling was of similar/higher benefit; in the medium term only counseling exerted 
a significant impact on patient’ outcomes. 
 
INTRODUCTION 
Cancer related malnutrition is multifactorial [1] and bears a negative prognosis [2, 3]. The 
risk of nutritional deterioration, particularly in cancers of the head and neck, increases during 
radiotherapy (RT) [4]. RT induced morbidity, e.g. mucositis, odynophagia, dysphagia, 
xerostomia, dysgeusia, nausea, vomiting and anorexia, is common and may compromise both 
nutrition as status and functional ability [5, 6], which in turn, impacts upon Quality of Life (QoL) 
[7]. The latter is a subjective multidimensional construct reflecting functional status, 
psychosocial well being, health and disease/treatment-related perceptions [8, 9]. Preliminary 
data support evidence-based benefits from oral nutritional intervention [10], and we have 
recently demonstrated the association between nutritional parameters and worse overall 
morbidity/QoL in cancer patients [11].  
This study was designed to test the hypothesis of a causal pathway between nutritional 
intervention and functional/clinical outcomes. Within this framework, we conducted a 
prospective randomized controlled trial in head-neck cancer (HNC) patients referred for 
radiotherapy. The study was designed to investigate whether and to what extent dietary 
counseling or oral nutrition commercial supplements during RT affected oral intake. Furthermore 
the impact of nutritional intake on predefined outcomes (nutritional status and Quality of Life) 
during treatment and at 3 months was examined.  
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MATERIALS AND METHODS 
This prospective randomized controlled trial was approved by the University Hospital Ethics 
Committee and was conducted in accordance with the Helsinki Declaration of 1975 as revised 
in 1983. All patients gave their written informed consent to participate in the study. Data were 
recorded on individual forms pre-constructed for statistical analysis. Between July 2000 and 
March 2003, all consecutive HNC ambulatory patients referred for RT were considered eligible, 
regardless of whether the proposed RT was primary, adjuvant to surgery, combined with 
chemotherapy or with palliative intent.  
For every patient and prior to RT planning, the medical staff registered the following: clinical 
variables, recent medications and chemotherapy, duration of the disease, cancer location, 
presence of distant metastases, and tumor burden according to TNM stage [12] determined by 
local and whole-body imaging methods. The duration of the disease, confirmed by histology, 
was defined as the length of time (in months) between symptomatic manifestations and study 
entry. Inclusion criteria were: referral for RT treatment of 70 Gy administered in 35 fractions, 
absence of renal disease and/or diabetes mellitus. Throughout RT, all medication and 
concurrent chemotherapy was registered, and acute RT induced morbidity was scored from 0 to 
4 according to the EORTC/RTOG criteria, in which higher scores indicate increased symptom 
severity [13].  
Study Design 
A minimum sample size of 40 patients was calculated to detect a difference in body weight of 
1.9 kg, in nutritional intake of 25% and in QoL scores of 20% (that is, an effect size of 0.9) with 
a significance level of 0.01 between groups and a power of 0.85. Statistical power was based 
on the changes observed in weight, nutritional intake and QoL from a pilot study conducted in 
36 patients with HNC [14, 15]. The present study therefore included 75 free-living patients (60M: 
15F), mean age 60±11 (range 36-79) years, with cancer of the base of the tongue, 
nasopharynx, oropharynx, larynx: 30 in stage I/II and 45 in stage III/IV. All patients were referred 
for pre-operative RT, having been previously treated with chemotherapy (5-Fluorouracil + 
Cisplatin + Folinic Acid based regimen).   
Patients stratified by cancer stage were randomized at enrolment in permutation blocks of 
three, using a sequential series of numbered opaque sealed envelopes containing computer 
generated random assignments. A copy of the randomization sequence was kept separately 
from the study personnel. Randomization envelopes were opened before the first appointment 
with the patients by a person blind to the study procedures.  
Randomized patients had scheduled visits and identical contact time with the research dietician 
(PR). All parameters and study measures were assessed as described in Table 1, and the use 
of other medications and dietary supplements and compliance with dietary recommendations 
were monitored weekly. 
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Table 1 Data collection, nutritional intervention and visit schedule 
Visit Baseline RT treatment period End RT 3 months 
 Study day 1 7 14 21 28 35 42 49 139 
Demography X         
Medical history X         
Informed consent X         
Randomization X         
Concomitant medications X X X X X X X X X 
Nutritional status with PG-SGA X X X X X X X X X 
Weight X X X X X X X X X 
Diet history X        X 
24-hour recall  X X X X X X X X 
RT induced morbidity with 
EORTC/RTOG 
  X X X X X X X 
QoL with EORTC QLQ-C30 X       X X 
*Nutritional intervention (G1, G2) X X X X X X X X  
Acceptability and compliance  X X X X X X X  
*Nutritional intervention period from day 1 to 42; RT: radiotherapy; PG-SGA: Ottery’s Patient Generated 
Subjective Global Assessment; G1: dietary counseling based on regular foods; G2: supplements. 
 
Overall, the main goal of both nutritional interventions was to enable every patient to achieve 
his/her calculated energy and protein requirements. Dietary counseling involved the prescription 
of a therapeutic diet using regular foods, which was further modified to provide for individual 
requirements. This was based on the need for an adequate intake and also took into 
consideration other relevant factors, namely the need for alleviation or arrest of local symptoms, 
as well as psychological factors and digestive and absorptive capacity. The therapeutic diet was 
adjusted to the individual’s usual diet, thereby recognizing personal eating patterns and 
preferences, which forms the basis for individualized dietary counseling. The prescription 
identified the type, amount and frequency of feeding, specified the caloric/protein level to attain, 
together with any restrictions and limited or increased individual dietary components [16].   
Oral nutrition commercial supplements, selected on the basis of the pilot study that identified 
protein as the main nutritional deficit [14, 15], were ready to use, high protein, energy dense 
liquid polymeric formulations, intended to act as a supplement to the patients’ usual diet. 
Supplements were offered to patients who were able to select their preferred flavors and were 
instructed to use them as drinks to be consumed in-between meals, in addition to any other 
meal. Supplements used throughout the study were always of the same commercial brand. 
Each 200 mL can provides 20g protein and 200 kcal. The amount of supplement provided was 
uniform, 2 cans/day and this covered the calculated requirements. Compliance was ensured by 
using a supplement consumption record which was kept daily by patients, and verified by a 
carer/relative. 
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Study Measures 
Nutritional Assessment was performed by using Ottery’s Patient Generated Subjective 
Global Assessment (PG-SGA) [17], a validated nutritional assessment tool for cancer patients 
that addresses: a) weight changes, symptoms (anorexia, nausea, constipation, mucositis, 
vomiting, diarrhea, xerostomia, pain), alterations in food intake by comparison with the usual 
intake, and functional capacity; b) components of metabolic stress: sepsis, neutropenic or tumor 
fever, corticosteroids, and c) physical examination: subcutaneous fat (triceps skinfold and at the 
level of the lower ribs in the midmaxillary line), muscle bulk and tone in the temporal, deltoids 
and quadriceps areas, ankle/sacral edema or ascites. Nutritional status was thus categorized in 
three degrees: normal, moderate and severe malnutrition.  
Nutritional Requirements and Dietary Assessment. Basal energy requirements were 
estimated using the World Health Organization formulae for patients aged ≤60 yrs [18] or by the 
Owen et al formulae for patients aged >60 yrs [19, 20], given their better performance in 
predicting resting metabolic rate [21]. To estimate patients’ daily energy requirements (EER), 
basal requirements were multiplied by a 1.5 activity factor [22]; daily protein requirements were 
estimated by comparison with age and sex standardized reference values, which range 
between 0.8 and 1.0 g/kg per day [22]. 
Nutritional intake was derived from a diet history [23, 24]; to assess changes in current 
intake during the RT treatment period a 24hr-recall food questionnaire was used [25]. In detail, 
the primary source of the dietary data was Burke’s diet history, which was further complemented 
by multiple and sequential 24-hour recall evaluations (2 week-days and 1 weekend day) 
undertaken at every scheduled visit. Both energy and protein intakes were always analyzed 
together. The software DIETPLAN version 5 for Windows (Forestfield software Ltd 2003, 
Horsham, UK) was used to analyze nutrient contents of regular foods and meals. 
QoL instrument. QoL was assessed at the 3 time-points (Table 1), always using the 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
version 3.0 (EORTC-QLQ C30). This instrument is a 30-item cancer specific questionnaire 
including 6 function scales (physical, emotional, cognitive, social, role, and global health/QoL), 3 
symptom scales (fatigue, pain, nausea/vomiting), and 6 single items assessing symptoms and 
the financial impact of the disease [8]. Higher scores on the function scales indicate better 
functioning whilst higher scores on the symptom scales and single items denote increased 
symptomatology or worse financial impairment. Original scores were linearly transformed to 
obtain quantified scores within the range of 0 to 100; in addition, and for better validation in the 
clinical context, overall scores derived from function scales, symptom scales and single items, 
were calculated on the basis of the very high statistical significance of the interscale 
correlations, which were calculated according to EORTC’s guidelines [8]. 
Statistical Analysis  
Statistical analysis was performed using SPSS 11.5 (SPSS Inc, Chicago, USA) and EPI–
Info 2000 (CDC, Atlanta, USA). All analyses were conducted on an-intention-to-treat basis, and 
therefore available data from all study patients were used. If any missing data were observed, 
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the missing value(s) would be replaced by the average of the study group, which would have no 
effect on the estimators. Study groups were assessed for comparability at study entry. Data 
related to incidence, prevalence or frequency (symptoms, cancer stages and nutritional status 
categories) were expressed as number and/or percentage; age was expressed as the mean ± 
standard deviation (range); energy and protein intakes were expressed as the median (range), 
and patients’ QoL scores were expressed as median values. Continuous variables were 
analyzed using one-way analysis of variance (ANOVA) or Wilcoxon rank sum tests as 
appropriate; categorical variables and incidence, prevalence or frequency were evaluated by 
the Chi-square test. Univariate or multiple correlations were assessed by two-tailed non-
parametric Spearman tests. Statistical significance was set for a p value < 0.05. 
 
RESULTS  
Patients’ distribution after randomization was as follows: G1 (n=25) received individualized 
dietary counseling based on regular foods, G2 (n=25) were asked to consume two cans per day 
of a high protein liquid supplement in addition to their usual diet, patients in the control group G3 
(n=25) were instructed to maintain their ad lib intake. All patients completed the study as 
outlined in Table 1 and there were no patients lost to follow-up; none was taking any other 
dietary supplements, either prior or throughout the period under scrutiny. 
Nutritional intake. At baseline, current energy and protein intakes for the three study groups 
were compared with EER and the protein median reference values, intakes were not 
significantly different between groups, Figure 1. 
 
 
 
 
 
 
 
 
The median nutritional intake patterns throughout the study are shown in Figure 2. 
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Figure 1 Patients’ median baseline estimated requirements  and median intake , nutritional intake was similar in all 
groups; energy intake was not significantly different from estimated requirements, protein intake was lower than 
reference values, p=0.05; G1=dietary counseling based on regular foods, G2=supplements, G3=ad lib intake. 
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At the end of RT by comparison to the onset, energy intake showed a net increase of 521 (358-
732) kcal/d in G1 (p=0.002) and of 322 (286-412) kcal/d in G2 (p=0.05); G1>G2, p=0.005. 
Energy intake decreased in G3, 400 (201-502) kcal/d (p<0.01). At the 3 months follow-up, all 
patients in G1 still complied with dietary recommendations as given during RT and maintained 
their energy intake, whilst in both G2 and G3 patients’ energy intake decreased (p=0.005) either 
to baseline or below baseline. In what concerns protein intake, there was a net increase of 26 
(20-34) g/d in G1 (p=0.006) and of 35 (20-44) g/d in G2 (p=0.001); G1<G2, p=0.06; in both G1 
and G2, the increase was always higher in stage I/II, p=0.05. Protein intake decreased in G3, 15 
(9-21) g/d (p<0.01). At the 3 months follow-up, patients in G1 complied with nutritional 
recommendations as given during RT and maintained their protein intake, whilst both G2 and 
G3 patients decreased (p<0.05) their protein intake either to baseline or below baseline. 
Nutritional status. The prevalence of malnutrition at baseline was similar between the three 
study groups (16 in G1, 14 in G2 and 15 in G3); 56% of the malnourished patients were in stage 
III and IV and 4% in stage I and II. The number of patients that presented further nutritional 
deterioration, both at the end of RT and at the 3-months follow-up, is shown in Table 2. 
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Figure 2 Energy and protein intake patterns during intervention and follow-up for the three study groups; G1=dietary 
counseling based on regular foods, G2=supplements, G3=ad lib intake. Energy: *G1>G2>G3 (p=0.005) and 
§G1>G2>G3 (p=0.001);  protein: **G2>G1>G3 (p=0.006) and §§G1>G2>G3 (p=0.001).  
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Table 2 Changes in nutritional status during RT and at 3-months categorized according to PG-SGA  
Methods  G1  G2  G3  p1 p2 
  Decline  Maintained/improved  Decline  Maintained/improved  Decline  Maintained/improved    
  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months    
PG-SGA   5 3  20 22  19 24  6 1  24 25  1 0  <.002 <.001 
Data are expressed as number of patients; NS = not significant; p1 expresses the significance of statistical differences between intervention groups, regarding nutritional 
decline both at the End RT and at 3 months; p2 expresses the significance of statistical differences between intervention groups, regarding maintenance/improvement of 
nutritional status at the End RT and at 3 months.  
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In G1, 8/16 malnourished patients at baseline improved their nutritional status with a net 
average recovery of 4 (2-6) kg at 3 months; conversely, none of the patients in G2 and G3 ever 
improved their nutritional status.  
Symptom induced morbidity. At the onset of RT, the prevalence of anorexia (≤7%), 
nausea/vomiting (≤10%), xerostomia (≤20%), dysgeusia (≤22%) and/or dysphagia/odynophagia 
(≤25%) did not differ between the groups. At the end of RT, overall more than 90% of the 
patients experienced RT-induced toxicity, the severity and incidence of which are presented in 
Table 3: the incidence of the above designated symptomatic manifestations was not 
significantly different between groups (p<0.08); though there was a trend for reduced 
syptomatology in G1 vs G2, G3 (p<0.07). Nevertheless, the incidence and/or severity of the 
symptoms improved differently in the three groups after RT. 
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Table 3 RT induced morbidity categorized according to severity grades (12) 
Symptoms  G1  G2  G3  p1 p2 p3 
  Grade 1  Grade 2  Grade 1  Grade 2  Grade1  Grade 2     
  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months  End RT 3 months     
Anorexia  10 1  2 0  9 4  5 3  9 5  7 3  <.05 <.12 <.001 
Nausea/ 
Vomiting 
 4 0  1 0  3 2  2 1  3 2  2 1  <.001 <.10 <.05 
Xerostomia  12 2  3 0  10 6  6 3  10 5  7 3  <.04 <.05 <.0003 
Dysgueusia  10 1  7 2  10 6  11 5  11 5  12 6  <.04 <.008 <.0004 
Odynophagia/ 
dysphagia 
 14 2  8 1  12 3  10 3  12 6  12 6  <.0001 <.05 <.0002 
Data are expressed as number of patients; grades 3 and 4 were never observed; p1 expresses the significance of statistical differences between intervention groups, regarding the 
reduction of grade 1 symptom’ incidence between the End RT and 3-months; p2 expresses the significance of statistical differences between intervention groups, regarding the 
reduction of grade 2 symptom’ incidence between the End RT and 3-months; p3 expresses the significance of statistical differences between intervention groups, regarding the 
reduction of grades 1+2 symptom’ incidence between the End RT and 3-months.  
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At 3 months, the reduction of incidence and severity of grade 1+2 anorexia, nausea/vomiting, 
xerostomia and dysgeusia was distinctly different between groups: 90% of the patients 
improved in G1 vs 67% in G2 vs 51% in G3 (p<0.0001); G1 > G2, G3 (p<0.07). The reduction of 
grade 1+2 dysphagia/odynophagia incidence and severity remained not significantly different 
between groups (p<0.09).  
In the 3 groups the different symptom pattern occurred despite adequate and appropriate 
prescription of medications to alleviate symptoms. During RT, oral anti-fungal solutions 
(nistatine), local anesthetics (lidocaine) and/or anti-inflammatory drugs were prescribed to 57% 
of patients in G1, to 61% in G2 and to 68% in G3 (NS).  
In order to clarify the influence of dietary intake and RT induced symptoms on patients’ 
nutritional decline, a two-tailed multiple correlation analysis was performed; dietary intake was 
significantly correlated with nutritional status in all study groups (r≤−0.59, p≤0.002).  
Quality of Life. Median QoL dimension scores for the study groups at the three evaluation set 
points are presented in Table 4. 
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Table 4 Median Quality of Life dimensions’ scores 
Items  G1  G2  G3 
  Onset End 3-months  Onset End 3-months  Onset End 3-months 
Function scales             
    Global QoL  48 75* 82#§  46 70* 62#  47 30* 30# 
    Physical function  49 74* 79#  48 69* 60#  45 21* 22# 
    Role function  50 78* 80#  52 68* 58#  48 20* 19# 
    Emotional function  55 79* 83#  50 66* 62#  51 28* 28# 
    Social function  52 82* 85#  51 66* 61#  49 19* 20# 
   Cognitive function  38 58* 60#  35 51* 54#  37 20* 20# 
Symptoms, scales             
    Fatigue  30 55* 26§  31 75* 78#  29 78* 79# 
    Pain  25 63* 15#§  22 74* 45#§  23 78* 73# 
    Nausea and vomiting  15 50* 10#§  14 71* 60#§  12 72* 73#§ 
Symptoms, single items             
    Dyspnea  15 39* 8#§  14 40* 38#  18 38* 38# 
    Sleep disturbance  30 55* 29#§  28 55* 75#§  32 60* 78#§ 
    Appetite  45 68* 48#§  40 59* 72#§  42 65* 75#§ 
    Constipation  12 10 10  11 9 8  9 8 8 
    Diarrhea  7 7 7  6 6 6  7 7 7 
    Finance  38 38 38  37 37 37  40 40 40 
 
 
 
 
 
 
 
 
At the end of RT in G1, despite RT induced symptoms, all QoL function scores improved 
significantly (p<0.003) and these were proportional to the increases registered in energy and 
protein intakes (r<0.83; p<0.001). There was also a linear positive association with the 
improvement in the patients’ nutritional status (p<0.05). In G2, all function scores improved 
(p<0.009) although these were only proportional to the increase in protein intake (r<058; 
p<0.05). In considering symptom scales and single items for both G1 and G2, pain worsened in 
association with odynophagia/dysphagia (p<0.04), and fatigue (more severe in G2) was 
G1: dietary counseling based on regular foods; G2: supplements; G3: ad lib intake; higher scores on function scales 
indicate better functioning, higher scores on symptom scales/single items denote increased symptomatology or 
worse financial impairment. 
 
 Highlights overall significant improvement,  highlights overall significant 
deterioration,  highlights overall non-significant deterioration; *significant differences between baseline end of RT; 
#significant differences between baseline and at 3-months; §significant differences between end of RT and at 3-
months.  
 
 118 
associated with anorexia (p<0.05); patients also reported increased severity of sleep 
disturbance and dyspnea (p<0.05). In G3, all QoL function scores worsened in association with 
a deterioration of their nutritional intake (p<0.0001), as well as of their nutritional status 
(p<0.002). All symptom scales significantly worsened (p<0.004): increased fatigue was 
associated with poorer nutritional intake (p<0.003) and with nutritional status deterioration 
(p<0.001), pain worsened in association with odynophagia/dysphagia (p<0.001); as far as 
symptoms and single items were concerned, sleep disturbance, appetite and dyspnea also 
grew worse (p<0.002).  
At 3-months follow-up and by comparison with the end of RT, all G1 patients maintained or 
improved their overall QoL, which was positively and proportionally associated with 
maintenance/improvement of nutritional status (p<0.008) and adequate dietary intake (p<0.01). 
Function scores improved or were maintained, and symptom scales/single items were now 
significantly better than baseline scores (p<0.002). G2 patients maintained or worsened their 
overall QoL (p<0.03) further reporting worse physical, role, emotional, and social functions 
(p<0.07); deterioration was associated with poor dietary intake (p<0.003) and depleted 
nutritional status (p<0.002). Notwithstanding the improvement of pain (p<0.06), the remaining 
scores were unchanged by comparison with the end of RT and were worse than at baseline 
(p<0.002). In G3, function scores further deteriorated both in relation to the baseline and to the 
end of RT (p<0.004), deterioration significantly associated with inadequate dietary intake 
(p<0.001) and deficient nutritional status (p<0.002). Symptom scores, with the exception of 
pain, remained as poor as reported at the end of RT and significantly worse than at baseline 
(p<0.003); the worst scores were associated with inadequate dietary intake (p<0.005). 
 
DISCUSSION 
Nutrition is a major issue in oncology; nutritional decline may ensue from the disease 
location and stage and its treatment(s) [1] and bears a negative prognosis [2]. Although 
symptomatic manifestations of radiation injury and their nutritional consequences have long 
been recognized [26], the potential role of adjuvant oral nutritional support on patients’ 
outcomes has not yet been explored. This prospective randomized controlled trial is the first to 
demonstrate that even in HNC, concurrent individualized dietary counseling, based on regular 
foods, is the most effective means of improving patients’ nutritional intake, status and QoL, 
thereby lessening radiotherapy induced morbidity.  
Weight loss during RT is an early indicator of nutritional decline [26]; in the absence of 
nutritional support, the majority of head-neck cancer patients submitted to a 6-7 week course 
with ± 70 Gy of RT reported weight loss [4]. In our trial and throughout the whole study period, 
including intervention and follow-up, nutritional deterioration was only observed in 20% of 
patients in G1 (dietary counseling), amounting to 76% in G2 (supplements) and to 96% of the 
G3 control patients. These findings are concordant with the fact that disease-related 
malnutrition is frequently caused by reduced dietary intake [27]. Indeed, although the three 
study groups at baseline showed comparable energy and protein intakes, nutritional intake 
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patterns were quite different according to the nutritional intervention. At the end of RT, G1 
showed the highest average energy intake sustained at the 3 months follow-up; the smaller 
increase in G2 was lost at follow-up when energy intake decreased to/or below baseline, as 
always registered in G3. Both dietary manipulation and supplements were effective protein 
intake restorers during the nutritional intervention phase; at 3 months the increase was just 
maintained in G1, whereas in the other 2 groups protein intake followed a pattern similar to the 
one observed for energy (Figure 2). Thus, within the context of this clinical trial, individualized 
dietary counseling during radiotherapy, taking into consideration the patients’ clinical condition 
and symptoms, was the most effective nutrition intervention assuring a sustained and adequate 
diet which was able to overcome the predictable deterioration subsequent to radiotherapy. 
Moreover, such nutritional outcomes concur with what has been proposed as the causal 
pathway, i.e. optimizing nutritional intake may be the most effective method for treating disease-
related malnutrition. There is evidence in a range of conditions to support the hypothesis that 
enabling the provision of the appropriate nutritional therapy leads to improved body weight and 
fat free-mass and that this generally reflects an improvement in protein-energy status [27]. 
The severity and extent to which patients experience radiotherapy induced toxicity, depend 
on location, tumor histology, total dose, fractionation, volume of irradiated area and injury repair 
mechanisms, which dictate susceptibility to acute radiation damage, during which high turnover 
cells are at higher risk [26]. The resulting nutritional sequelae occur through direct effects on 
oral, pharyngeal and laryngeal neoplastic and healthy tissues, accentuating physical discomfort 
and symptoms, e.g. xerostomia, disgeusia, odynophagia, dysphagia, anorexia, 
nausea/vomiting, which further decrease nutritional intake [28-30]. So far, the routine clinical 
approach is to maintain ad lib oral feeding, although comparative studies of functional, clinical 
and QoL outcomes which can be achieved via dietary manipulation or through oral nutrition 
supplementation, are lacking [27]. Our study is the first to demonstrate that the nutritional 
content of the patient’s diet based on regular foods with appropriate manipulation, and not just 
protein and calorie supplementation, is the key to improving nutritional intake as well as some 
local symptomatic morbidity derived from mucosal damage, during radiotherapy and in the 
medium term. Indeed, dietary modifications may modify the ecology of the oral cavity by means 
of stimulating salivary secretion, and it is possible to decrease the oral intolerance to foods, both 
central to the pathogenesis of radiation injury severity [31].  
QoL assessment measuring the patients’ experiences of the impact of disease/therapy, 
expectations and satisfaction should be the gold standard as an independent end-point in 
clinical trials [32, 33]. Patients experience functional limitations, cognitive alterations and 
emotional stress, and overall QoL depends on both physical and psychological well being [7, 8, 
34]. All these aspects may influence or be influenced by nutrition although the relationship 
between poor nutritional parameters and QoL remains widely underestimated [35, 36]. Our 
group was the first to show that nutrition is a key determinant of QoL in cancer patients [11]. In 
this clinical trial, both at the end and at 3 months after RT, dietary counseling (Group 1) 
significantly improved all QoL function scores in association with an adequate dietary intake and 
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nutritional status. In patients who received oral supplements (G2), function scores improved 
during supplementation, but to a lesser extent than in G1, and also proportionally to the 
increase in diet intake; however, once the supplementation was discontinued most function 
scores deteriorated. Patients not submitted to any nutritional intervention (G3) experienced, 
throughout the whole study, a significant deterioration in function scores and fatigue, in direct 
relation to the worsening of their nutritional intake and nutritional status. Therefore, our results 
emphasize that “the impairment in structure, function and well being that form malnutrition, are 
nutritionally responsive” [27].   
Furthermore, the benefits of nutritional intervention on QoL were extendable to improved 
physiological function and overall clinical outcome. During RT, QoL symptom scales and single 
items’ scores deteriorated in all groups, though more pronounced in the ad lib group; most of 
these scales were also worse in G2 vs G1. In the medium term, G3’ symptom scales and single 
items remained as poor as those reported at the end of RT and worse than at the onset; worse 
scores were again associated with inadequate nutritional intake. Conversely, in G1 patients all 
the above mentioned scales were now improved and significantly better than their baseline 
scores, whereas in G2 there was an improvement in pain, though not as relevant as the 
improvement observed in G1. These results in patients who experience persistent eating 
difficulties support the concept that increased intake of an appropriate mixture of nutrients using 
regular foods will be of major benefit in modulating outcomes.  
Despite the expected, and experienced, detrimental effects of radiotherapy, multiprofessional 
patient’ management allowed proper assessment of nutritional status and nutritional 
requirements, dietary counseling, education and monitoring of diet compliance and timely 
management of symptoms. Nutrition intervention was central to the improvement of head-neck 
cancer patients’ nutritional as well as non-nutritional outcomes: nutritional intake, status, 
symptoms and QoL even in the medium term. Adding oral nutritional supplements to the diet did 
not appear to be as effective as dietary counseling. Early intervention and sensible partnerships 
with patients are key to success.  
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DISCUSSION AND FUTURE PERSPECTIVES 
Nutrition is clearly and consistently associated with cancer. It constitutes one of the most 
significant risk factors for the development of oncological diseases [1], and later on throughout 
the disease course, 8-84% of the patients will suffer from undernutrition [2] which will be the 
immediate cause of death of 20% of the patients with cancer [3]. The present Thesis was driven 
by the complexity of this multidirectional interrelation.  
Overall, the studies herewith presented were conducted in the difficult and diverse clinical 
setting of patients with cancers of the head and neck, oesophagus, stomach and colon/rectum. 
The results represent a breakthrough in demonstrating, beyond any doubt, the major 
importance of nutrition in cancer and its key role in patients’ well-being, Quality of Life and 
tolerance to treatments, in a disease whose aggressiveness bears a heavy burden that patients 
have to carry, adapt to and live with. These findings were followed by a clear scientific 
demonstration in the two prospective randomised controlled trials of nutritional therapy, 
conducted in two very distinct diagnoses such as head and neck cancer and colorectal cancer. 
Both clearly argue for the integration of Nutrition as part of a team approach for cancer 
treatment and patient’ management and do recognise the importance and necessity of good 
nutrition as therapy. Altogether the evidence produced definitely constitutes a step forward, 
which should strengthen the recognition of patients’ right of expecting adequate nutrition care, 
mandatory to sustain life throughout the disease journey. 
 
EVALUATION OF MULTIPLE INTERACTIONS STUDIES 
Nutritional deterioration in cancer is a highly complex end-result of multiple interactions 
which are most likely individual to the unique combination of each patient and the tumour [4]. 
Some of the implicated factors have been addressed in this Thesis. 
Greater understanding of factors contributing to nutritional deterioration in cancer, as well as 
patients’ expectations and the personal impact of the disease, are required to devise meaningful 
nutritional therapy. Despite the major importance of the tumour burden for the host, the pattern 
and/or progression of nutritional deterioration are also highly influenced by the cancer location 
[4]. In what concerns nutrition and its impact on the patients’ Quality of Life, although the 
location and stage of the disease are globally the major QoL determinants, nutritional aspects 
are equally important for functional scores, mainly for some diagnoses: head-neck, 
oesophageal cancer, in which the impact of nutritional deterioration combined with deficiencies 
in nutritional intake may, from a clinical perspective, be as relevant as the stage of the disease 
process [5, 6]. Specifically, in the cross-sectional study of 205 patients with cancer of the head-
neck, oesophagus, stomach, colon/rectum, nutritional deterioration was multifactorial and 
mainly determined by the tumour burden [4]. In a larger cohort of 271 patients, although cancer 
stage and location were the major determinants of the patients’ Quality of Life, nutritional 
deterioration combined with deficiencies in nutritional intake were functionally more relevant 
than cancer stage [5]. 
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RANDOMISED CONTROLLED TRIALS OF NUTRITIONAL THERAPY 
Based on this background, we tested the potential role of nutritional therapy on patient 
predefined outcomes: nutritional status, diet intake, morbidity and Quality of Life. Two 
prospective randomised controlled trials were conducted in patients with cancer of the 
colon/rectum (n=111) [7] or head-neck (n=75) [8]; in both instances patients were stratified for 
cancer stage. In order to compare nutritional therapy during radiotherapy, each study had 3 
arms: individualised dietary counselling vs ad libitum intake supplemented with commercial 
supplements vs ad libitum intake; outcomes were analysed at the end and 3 months after 
radiotherapy, the latter period without nutritional intervention.  
During radiotherapy and in both trials, only patients who received any form of nutritional 
intervention had a positive improvement in all outcomes; 3 months after the combined treatment 
period, only individualised nutritional counselling had a carry-over effect central to the 
improvement of various patient outcomes: nutritional intake, nutritional status, QoL and 
lessened morbidity. Oral nutritional supplements in addition to the ad libitum diet were not as 
effective as dietary counselling. Both clinical trials demonstrated that concurrent individualised 
dietary counselling based on regular foods, was the most effective means of improving patients’ 
nutritional intake, status and QoL during RT, which were sustained 3 months after its 
completion, thereby lessening RT induced morbidity [7, 8]. 
Cancer patients do really benefit from multiprofessional patient management; it must include 
a proper assessment of nutritional status and nutritional requirements, dietary counselling, 
education and monitoring of diet compliance and timely management of symptoms. Nutrition is 
central to the improvement of a diversity of patient outcomes in colorectal and head-neck 
cancer patients. The integration of early intensive nutritional intervention and sensible 
partnerships with patients is key to success. 
 
FUTURE PERSPECTIVES 
Still many doubts persist in what concerns the dynamics that may lead to or be the cause of 
cancer-related wasting [9, 10]. 
We are currently exploring potential mechanisms implicated in cancer-related metabolic 
dysfunction and nutritional wasting, namely, the measurement of resting energy expenditure 
and its possible association with various clinical variables (cancer stage, histology), circulating 
concentrations of inflammatory cytokines and their genetic polymorphisms, and to investigate 
whether an interrelationship among all these variables exists. Some of the specific questions 
are: 
1. What are the major determinants of patients’ resting energy expenditure? 
2. Does radiotherapy has any effect on the circulating concentrations of inflammatory 
cytokines (IL-1ra, IL-6, IL-10, TNF-α, IFN-γ and VEGF) and if so, how does that effect 
may be reflected on wasting components (resting energy expenditure, weight loss, 
nutritional intake)?  
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3. Are the concentrations of inflammatory cytokines correlated with each other and with 
cancer-related variables (stage, histology)? 
4. Is there a relationship between the presence of polymorphisms and the 
clinical/nutritional outcome of the patients? 
5. Is there a relationship between the presence of polymorphisms, the circulating 
concentration of inflammatory cytokines, cancer-related variables and wasting 
components?   
 
Indeed, much needs to be investigated in cancer wasting and the putative involved 
components; our preliminary, yet unpublished, data on this topic (data not shown) do suggest 
that the composite wasting syndrome appears to ensue from a complex construct in which 
tumour histology and invasiveness along with released pro-inflammatory cytokines, namely IL-
1ra, IL-6, TNF-α IFN-γ, bear different burdens in the various wasting components with a 
maladaptive response to weight loss [11, 12]. Undoubtedly, cancer and nutrition provide a wide 
range of possibilities for future relevant research.   
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